Eulogy for David White (1946-2017)

delivered by Dr William Wall

at St. John the Divine Anglican Church, Arva, Ontario

on 14th June 2017

David White was my longtime friend and colleague. He was a dedicated scientist whose contributions are rightly measured on a global scale.

Our friendship began more than four decades ago in Cambridge when we were fortunate to share the same mentor, Professor Roy Calne. David was a researcher in Sir Roy’s Department of Surgery. He had just finished his PhD in immunology and he was studyingsolutions to rejection of transplanted organs. I was there for two years to learn transplant surgery. It was the mid-1970s. We always joked later that he tried his best to teach me immunology and I tried my best to teach him surgery, but neither had great success. David’s keen intellect and breadth of knowledge were immediately evident to me however, as they were to all of his colleagues. He had the ability to see a problem from several perspectives – such an important quality in people committed to research.

The field of transplantation was languishing at that time. Knowledge of rejection was incomplete and methods to control it were inadequate. The clinical results were so dismalthat most believed its future was questionable. That all changed the year after I left Cambridge when Sir Roy obtained a completely new drug – cyclosporine – and showed first in the laboratory and then in patients its effectiveness in controlling rejection. Those pivotal studies transformed transplantation into one of the greatest achievements of modern medicine. David was Sir Roy’s closest collaborator in those studies and much research that followed. It was a spectacular success story. Our own Canadian pioneer in transplantation, Calvin Stiller, recognized the potential for this new drug when the first reports from Cambridge began to surface. He knew the importance of obtaining it for use in Canada.

As one would expect with such a major breakthrough, everyone involved in transplant efforts at the time was desperate to get cyclosporine. For transplant specialists, it was the equivalent to getting some of the first samples of penicillin after its discovery.

Well, David White brought to us, in London, the very first sample of the drug to leave theUnited Kingdom. It was the winter of 1978 when I met David outside the baggage claim of Pearson airport. After exchanging greetings, the first words off my lips were “Did you bring the cyclosporine?” He reached into his breast pocket and with a smile produced a vial of the magic white powder. It was so precious that he did not risk losing it by putting it in checked luggage. But can anyone imagine today trying to board an aircraft with a stash of white powder in your pocket?! That’s what David did in 1978.

1

That sample was important, I believe, to Dr. Stiller securing more cyclosporine and conducting in Canada the world’s first randomized trial in kidney patients. The results were as dramatic as expected, and they propelled our centre forward at a particularly exciting time in transplantation. So we, Canada, Canadians are indebted to Sir Roy and David for their willingness to share the drug with us at the earliest time in its remarkable history.

There was an ensuing avalanche of activity worldwide with organ grafts and within several years tens of thousands of patients were taking cyclosporine. It became the cornerstone of immunosuppression for the next 20 years. There was an excellent and fruitful exchange of information between Cambridge and London. David was always open to sharing his latest research, whether in correspondence, on the phone or at meetings – and there were many.

After the success of cyclosporine, David redirected his research at solving what became the most pressing problem in transplantation, namely the inadequate number of donor organs. He approached it with his typical determination and enthusiasm. He produced genetically engineered pigs with the objective of establishing an unlimited source of organs – xenotransplants – transplants between species. He and colleagues in the United Kingdom developed the first transgenic pigs, animals carrying human genes that were meant to protect the organs from destruction by the vigorous immune response that typically defeats attempts at transplants between species. His research was central to our attempts to recruit David to London to occupy the then newly-established Stiller/NovartisChair in Xenotransplantation at Western. It wasn’t easy for him to leave his beloved Cambridge, but he ultimately accepted the London offer and moved to Canada in December 2000. He had cross-appointments in the Departments of Pathology, Microbiology and Immunology, and Surgery. David had a wonderful capacity to work with others. He was always quick to acknowledge the contributions of others, a particularly appealing trait of David’s.

He must have forgotten the cruel winter from when he visited in 1978 because he arrived with no boots and the thinnest of overcoats. Our housewarming gift for him was a snow shovel! After a single winter of shoveling snow, he did the Canadian thing and bought a snow blower. One year later he exercised good British judgment and hired a snow removal company to keep his driveway clear! Both the shovel and the snow blower continue to gather dust in his garage.

Xenotransplants using genetically modified pig organs have not been successful yet, but recent research using new technology to alter genes – something called CRISPR – may be the answer and the approach follows on David’s original concept. Before he became ill he was studying the use of insulin-producing cells from pig pancreases to cure diabetes. It just might be that another exciting era in transplantation is imminent. And, if that is the case, I believe that David’s full legacy is yet to be written. A few months ago he was notified by the International Xenotransplantation Association that he had been chosen to receive its highest honour. It’s a lectureship named after Keith Reemtsma, the

2

surgeon who attempted transplants between chimpanzees and humans in the 1960s. David was meant to give the Reemtsma Lecture at the meeting of the Association in Baltimore in September. The citation reads “the lecture will honor an eminent scientist, recognizing her or his contributions to the field of xenotransplantation”. David’s family will accept the honor for him. This was the last of many recognitions for his remarkable contributions.

Conversations with him were always enjoyable. His insightful comments and views on just about any subject revealed an intellectual curiosity that was impressive. He seemed to have an inexhaustible supply of rhymes for just about any occasion. When my sons were young, he entertained them in our home many times with rhyme after rhyme that always kept their full attention. David enjoyed the recitations as much as the children.

The full challenge of recovery from his mouth and neck surgery 18 months ago was a concern to many of us who were familiar with the type of cancer operation he was going to have, especially for regaining the ability to speak afterwards and pronounce words. This was particularly important for David who was an eloquent speaker. But David dealt with it positively and without complaint, essentially learning to speak again. There was never a hint of him trying to obscure any perceived deficit by remaining silent. Rather, heovercame it by deliberately speaking, being as articulate as he could, even at conferences with many in attendance. His resolve was admirable.

By all measures David had a distinguished career. He served on the editorial boards of seven journals, he published extensively and he lectured widely. His research was dedicated to the relief of human suffering. He was a good person, a valued colleague, anda fine friend.

Bill WallJune 14, 2017

3

CURRICULUM VITAE

David James Graham White

Professional Address: The Schulic School of MedicineUniversity of Western OntarioThe Siebens Drake Centre 1400 Western RoadLondon OntarioCanada N6G 2V4

Nationality: Canadian/British dual citizenship

EDUCATION:

Dulwich College Preparatory School, 1952-1959Eleven plus and CSE exams

Epsom College, 1960-196611 GCE 'O' Levels, 3 'A' Levels

University of Surrey (1966-1969) Part I Anatomy, Physiology, Biochemistry Part II Medical Microbiology and Pathology Qualified as Computer Programmer (Algol 60) 1969Awarded BSc (Hons) Distinction in Part II 1969

Churchill College, Cambridge (1969-1975)Med. Sci. Tripos 1972PhD 1975

University of Cambridge Clinical School Membership of the Royal College of Pathologists 1984Fellowship of the Royal College of Pathologists 1996

4

APPOINTMENTS:

Post Doctoral Research Fellow, Department of Surgery, University of Cambridge, 1975-1976.

Assistant Director of Research, Department of Surgery, University of Cambridge, 1976-1979.

Research Scientist, 1er echelon CNRZ, Jouy-en-Josas, Paris, France, (sabbaticalappointment) 1976-1977.

Senior Research Associate, Department of Surgery, University of Cambridge, 1979-1984.

Lecturer in Transplantation Immunology, (Associate Professor, tenured) Department ofSurgery, University of Cambridge, 1984 - 2000 (Merit award promotion 1990).

Chief Scientific Officer and Co-Founder Imutran Ltd 1986-1996

Therapeutic Area Head and Member of Novartis global Research Board 1996- 2000

Robarts Research Institute Scientist 2000-2007

Novartis/Stiller Professor of Xenotransplantation University of Western Ontario 2000-2012

Director Islet Isolation Laboratory LHSC 2002- 2007

Professor Department of Surgery University of Western Ontario 2002- 2012

Professor Department of Pathology University of Western Ontario 2002- 2013

Professor Department of Microbiology and Immunology University of Western Ontario2003- 2008

Chief Scientific Officer Founder and SAB Chairman Sernova Corp 2006-

Emeritus Professor of Surgery University of Western Ontario 2012-

OTHER AWARDS AND APPOINTMENTS

5

MRC/CRM Scholarship - 1976

Travelling Fellowship, NIH Bethesda - 1979

Editorial Board, Transplantation - 1981

Organizing Committee, First International Congress on Cyclosporine 1982

Visiting Professor, Northwestern University at Evanston, Illinois - 1982

Officer of the Council of the British Transplantation Society - 1983

Council Member, British Society of Immunology - 1984

Editorial Board, Clinical and Experimental Immunology - 1985

Supervisory Committee, The (International) Transplantation Society - 1986

Scientific Advisory Board, Lazards Bank (Medical Ventures Division) - 1987

Director, Imutran Ltd -1988

The Panhellenic Nephrological Congress Prize - 1989

Lancet Editorial Review Board -1990

Scientific Advisory Board Medical Partners Management Corporation -1990

Elected to Athenaeum - 1990

University of Cambridge merit award - 1990

ESOT award for Science - 1991

Editorial Board, Transplant International - 1992

Editorial Board, Xeno - 1994

Editorial Board, Xenotransplantation - 1994

Editorial Board, Journal of Heart and Heart-Lung Transplantation -1994

Visiting Professorship, Mayo Clinic - 1995

Medal of Honor Yonsei University College of Medicine 1996

6

Lakaresallskapet Lecture Swedish Transplantation Society 1998

The George Lecturer in Thoracic Transplantation Vanderbilt University 1998

Member UK government (DTI) Foresight committee for health care 1999

Member BBSRC steering committee on GAIT (Genome Analysis of Agriculturally Important Traits) 1999

Selection board King Faisal International Prize for Medicine 2000

Euro-Transplant Memorial Lecture 2001

Secretaries (USA) Advisory Council on Xenotransplantation 2002 & 2004

Advisory Committee Prince Mahidol Foundation 2003

Ontario Graduate Scholarship Committee 2005

Chairman Sernova Scientific Advisory Board 2006

Supervisory Board Ontario Ministry for Science and Innovation 2008

Fellow of the Royal Society of Medicine 2010

RCPath Governance & Immplementation Group 2012

MITACS College of scientific advisors 2013

Member of:British Transplantation SocietyBritish Society of ImmunologistsThe Transplantation SocietyEuropean Society of Organ TransplantationInternational Xenotransplant AssociationRoyal College of PathologistsThe Athenaeum

Research Funding for the past 5 years

Title Development of Local Immune ProtectionSource National Research Council of CanadaRole Scientific Director (PI)Date 2013-2014Amount $940,000

Title Analysis of Islet Neogenesis

7

Source MITACSRole ConsultantDate 2012-2014Amount $56,000

Title Islet Autografting in PigsSource National Research Council of Canada -IRAPRole Scientific Director (PI)Date 2009-2010Amount $980,000

Title Reversible immortalization and P16 regulation of senescenceSource Canadian Institutes of Health Research (CIHR)Role Principle applicant (PI)Date 09/2006 – 08/2009Amount $298,183

Title Co-transplantation of porcine islets and Sertoli cellsSource Crimson IncRole Scientific director (PI)Date 08/2006 – 07/2009Amount $3,200,000

Title Development of cellular magnetic resonance imaging techniquesSource Canadian Institutes of Health Research (CIHR)Role Co-applicantDate 04/2006 – 03/2009Amount $413,406

Title Imaging the islets of Langerhans in vivoSource Alan Thicke Centre for Juvenile DiabetesRole Principal Applicant (PI)Date 01/2005 – 12/2006Amount $230,000

Title Clinical islet laboratorySource London Health Science CentreRole Director (PI)Date 09/2004 – 12/2006Amount $1,200,000

Title Studies in xenotransplantationSource Canadian Foundation for InnovationRole Principle applicant (PI)Date 09/2002 – 08/2005

8

Amount $3,200,000

Title The London InnovariumSource Canadian Foundation for InnovationRole Co-applicantDate 06/2002 – 05/2005Amount $28,000,000

Students Supervised in the past 5 years

Name of Student

ProgramType

Dates DegreeReceived orexpected

Year Project title

Andrew Pepper

Hongji Yang

Andrew Pepper

Dalibor Kubelik

Kelvin Shek

James Melling

Iram Siddqui

Laura Copeman

John Neu

Joo-Ho Tai

Rosales Hernandez

Farah Bahatti

Graduate student

Graduate student

4th year student

Graduate student

4th year student

Postdoctoral fellow

Graduate student

Graduate Student

Postdoctoral fellowPostdoctoral fellowPostdoctoral fellowClinician/scientist

06/2007 -07/2012

03/2006 –

09/2006-04/2007

07/2005 –09/2007

09/2005- 04/2006

05/2005- 08/2007

02/2005-06/2009

01/2005-05/2007

12/2001-11/2007

06/2002-02/2006

03/2003-04/2005

09/1998-08/2003

PhD

PhD

Bachelors

Masters

Bachelors

PhD

Masters

Masters

PhD

PhD

PhD

MD (UK)

2007

2007

2006

2002

2009

2007

2001

1996

2002

2003

Islet function

Xenotransplantation pig-to primate

O2 consumption

Inhibition of vascular rejection

FasL expression

Islet xenotransplantationInduction of tolerance

Modulation of immune responses

Immortality

Chimerism

Pig to primate cardiac xenotransplants

9

PUBLICATIONS

Calne RY, Davis DR, Hadjiyannakis E, Sells RA, White DJG, Herbertson BM, Millard P,Joysey V, Davies DAL, Binns RM, Festenstein H. (1970) Immunosuppressive effectsof soluble cell membrane fractions, donor blood and serum on renal allograft survival.Nature 227: 903.

Calne RY, Davis DR, Hadjiyannakis E, Sells RA, White DJG, Herbertson BM,Millard PR, Joysey VC, Davies DAL, Binns RM, Festenstein H. (1971)Immunosuppressive effects of soluble antigens on renal allograft survival. MinervaChirurgica 26: 703-708.

Binns RM, Symons DBA, White DJG. (1972) Demonstration of the movement ofhistocompatibility antigen and immunoglobulin on the pig lymphocyte membrane byimmuno-fluorescence. J Physiol 226: 33.

Bradley BA, White DJG, Calne RY, Dunn DC. (1973) Lymphocyte gene products -Their relevance in renal allograft survival. IRCS 3: 29-5-1.

White DJG, Bradley BA, Calne RY, Binns RM. (1973) The relationship of thehistocompatibility locus in the pig to allograft survival. Transplant Proc 5: 317.

Bradley BA, White DJG, Calne RY, Dunn DC, Bitter-Suermann H, Sampson D,Herbertson BM. (1973) Genes determining mixed lymphocyte reactions: Their use inpredicting renal allograft survival. In: Proceedings of the Eighth Leucocyte CultureConference. Academic Press, p 85.

White DJG. (1974) Pig Leukocyte Antigens. PhD Thesis to University of Cambridge.

Bradley BA, White DJG, Edwards JM. (1974) A comparison of lymphocytepolymorphism defined independently by serology and mixed lymphocyte culture. TissueAntigens 4: 283.

Bradley BA, Calne RY, Bitter-Suermann H, Dunn DC, Pawelec G, Sampson D,Vasile C, White DJ.G. (1975) Clonal inhibition in naturally tolerant pigs. TransplantProc 7: 375.

Davies H ffS, Daniel MR, Taylor JE, Wakerley CAL, White DJG. (1975) Differencesbetween pig tissues in the expression of antigens of the major histocompatibilitycomplex. IRCS J Med Sci 3: 581.

Davies H ffS, Daniel MR, Taylor JE, Wakerley CAL, White DJG. (1975) Differentialexpression of antigens of the major histocompatibility complex by pig liver and kidneyparenchymal cells; possible relevance to organ allografts. IRCS J Med Sci 3: 582.

10

De Bono D, White DJG. (1976) The classification of lymphocyte adherence toendothelium. IX World Conference European Society for Microcirculation. University ofAntwerp, p 48.

De Bono D, MacIntyre D, White DJG, Gordon J. (1977) Endothelial adenine uptake asan assay for cell or complement mediated cytotoxicity. Immunology 32: 221.

De Bono DP, White DJG. (1977) The classification of leucocyte adherence toendothelium. Bibliotheca anatomica.

Kostakis AJ, White DJG, Calne RY. (1977) Toxic effects in the use of Cyclosporin Ain alcoholic solution as an immunosuppressant of rat heart allografts. IRCS J MedSci 5: 243.

Kostakis AJ, White DJG, Calne RY. (1977) Prolongation of rat heart allograft survivalby Cyclosporin A. IRCS J Med Sci 5: 280.

Calne RY, White DJG. (1977) Cyclosporin A - A powerful immunosuppressant indogs with renal allografts. J Med Sci 5: 595.

Davies HS, Taylor JE, White DJG, Binns RM. (1978) Major transplantation antigens ofpig, kidney and liver. Comparisons between the whole organs and their parenchymalconstituents. Transplantation 25: 290.

Calne RY, White DJG, Rolles K, Smith DP, Herbertson BM. (1978) Prolonged survivalof pig orthotopic heart grafts with Cyclosporin A. Lancet 1:1183-1185.

Dunn DC, White DJG., Wade J. (1978) Survival of first and second kidney allograftsafter withdrawal of Cyclosporin A therapy. IRCS J Med Sci 6: 464.

Calne RY, White DJG. (1978) Improved survival in human liver allografts. Eur J SurgRes 10: 292.

Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN,Pentlow BD, Rolles K. (1978) Cyclosporin A in patients receiving renal allograftsfrom cadaver donors. Lancet 2: 1323-1327.

White DJG, Plumb AM, Pawelec G, Brons G. (1979) Cyclosporin A. Animmunosuppressive agent preferentially active against proliferating T cells.Transplantation 27: 55-58.

White DJG, Calne RY, Plumb A. (1979) Mode of Action of Cyclosporin A. A newimmunosuppressive agent. Transplant Proc 11: 855-859.

Calne RY, White DJG, Pentlow BD, Rolles K, Syrakos T, Ohtawa T, Smith DP,,McMaster P, Evans DB, Herbertson BM, Thiru S. (1979) Cyclosporin A. Preliminary

11

observations in dogs with pancreatic duodenal allografts and patients with cadavericrenal transplants. Transplant Proc 11: 860-864.

White DJG, Lunney J. (1979) Transplantation in Pigs. Transplant Proc 11: 1170-1173.

Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, RollesK. (1979) Cyclosporin A in clinical kidney grafting from cadaver donors.Proc.Eur.Dial.Transplant.Assoc. 16:305-9:305

Pawelec G, Davies H ffS, White DJG, Brons G. (1979) Stimulation of lymphocyteproliferation in vitro by cultured non lymphoid tissue cells which do not express Iaequivalent antigen. Transplant Proc XI: 1095.

Dunn DC, White DJG. (1979) Studies of the action of Cyclosporin A on rabbit renalallografts. Eur J Surg Res 11: 88.

Dunn DC, White DJG, Herbertson BM, Wade J. (1979) Prolongation of kidney survivalduring and after Cyclosporin A therapy. Transplantation 27: 359-361.

Calne RY, White DJG, Rolles K, Thiru S, Evans DB, McMaster P, Dunn DC, CraddockGN, Henderson RG, Aziz S, Lewis P. (1979) Cyclosporin A initially as the onlyimmunosuppressant in 34 recipients of cadaveric organs, 32 kidneys, 2 pancreases and 2livers. Lancet ii: 1033-1036.

Zimmermann FA, White DJG, Gokel JM, Calne RY. (1979) Orthotopic livertransplantation in rats. Prolonging of survival time of allotransplants using CyclosporinA in an acute rejection model. Chirurgisches forum fur experimentelle und klinischeforschung, 339-44:339.

Timmermann W, Calne RY, White DJG, Thiede A. (1980) Action of Cyclosporin A andCytimun on the survival time of accessory heart transplants (author’s transl.)Chir.Forum.Exp.Klin.Forsch 139-43:139

Zimmermann FA, White DJG, Grantzow R, Dietz HG, Dorn-Kling S, Gokel JM. (1980)Immunosuppressive therapy in liver and small bowel grafts in the rat. (author’s transl.)Zeitschrift fur Kinderchirurgie, Band 30, Heft, 2: 177-180.

Dunn DC, White DJG, Herbertson BM, Rolles K. (1980) Detrimental effect of steroidson Cyclosporin A induced prolonged allograft survival. Transplant Proc 12: 335-338.

White DJG, Rolles K, Ohtawa T, Turell O. (1980) Cyclosporin A induced long termsurvival of fully incompatible skin and heart grafts in rats. Transplant Proc 12: 261-265.

McMaster P, Walton RM, White DJG, Medd RK, Syrakos TP. (1980) The influence ofischaemia on the biliary tract. Br. J.Surg. 67:321

12

White DJG. (1980) Cyclosporin A: Clinical Experience. Medical Research CouncilBulletin 8: 7-8.

Dunn DC, White DJG, Herbertson BM. (1980) Persistent non-specificimmunosuppression after a course of Cyclosporin A. Transplantation 29: 349-351.

Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN,Rolles K. (1980) Cyclosporin A in clinical kidney grafting from cadaver donors.Transplantation and Clinical Immunology XI: 48-53. Symposia fondation Merieux 3Excerpta Medica, Amsterdam.

Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Henderson R, Hamilton DL, BooneN, McMaster P, Gibby O, Williams R. (1981) Cyclosporin A in clinical organ grafting.Transplant Proc XIII: 349.

Cooper MR, Heise ER, Richards F, Muss HB, White DJG, Rhyne L, Howard V, SpurrCL. (1981) A prospective study of histocompatible leukocyte and platelet transfusionsduring chemotherapy of adult acute nonlymphocytic leukemia. Med.Pediatr.Oncol.9:225

Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Henderson R, Hamilton DL, BooneN, McMaster P, Gibby O, Williams R. (1981) Cyclosporin A in clinical organ grafting.First Northern Ireland Kidney Research Fund Lecture. Ulster.Med.J. 50:62

Calne RY, Rolles K, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, CraddockGN, Henderson RG, Aziz, Lewis P. (1981) Cyclosporin A in organ transplantation.Adv.Nephrol.Necker.Hosp 10:335-47:335

Calne RY, White DJG, Evans DB, Thiru S, Henderson R, Hamiton DV, Rolles K,McMaster P, Duffy TJ, MacDougall BRD, Williams R. (1981) Cyclosporin A incadaveric organ transplantation. BMJ 282: 934.

McMaster P, Gibby OM, Calne RY, Loke M, Luzio SP, Rolles K, White DJG, Evans DB.(1981) Human pancreatic transplantation: preliminary studies of carbohydrate control.Transplant Proc XIII: 371.

White DJG. Timmermann W, Davies HS, Nagao T, Kasahara K, Plumb A. (1981)Properties of Cyclosporin A induced graft acceptance. Transplant Proc XIII: 379.

White DJG, Plumb A, Calne RY. (1981) The immune status of transplant recipientsimmunosuppressed with Cyclosporin A. Transplant Proc XIII: 1666.

Hamilton DV, Calne RY, Evans DB, Henderson RG, Thiru S, White DJG. (1981) Theeffect of long-term Cyclosporin A on renal function. Lancet I: 1218-1219.

13

Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Henderson R, Hamilton DV, BooneN, McMaster P, Gibby O, Williams R. (1981) Cyclosporin A in Clinical OrganGrafting. Dialysis and Transplantation 10: 577-588.

Hamilton DV, Evans DB, Henderson RG, Thiru S, Calne RY, White DJG, CarmichaelDJ. (1981) Nephrotoxicity and metabolic acidosis in transplant patients on CyclosporinA. Proc Eur.Dial.Transplant.Assoc18: 400-9:409.

Calne Ry, Rolles K, White DJG, Thiru S, Evans DB, Henderson R, Hamilton DL, BooneN, McMaster P, Gibby O, Williams R. (1981) Cyclosporin A in clinical organ grafting.First Northern Ireland Kidney Research Fund lecture. Ulster. Med. J. 50:62

Calne RY, Rolles K, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, CraddockGN, Henderson RG, Aziz S, Lewis P. (1981) Cyclosporin A in organ transplantation.Adv.Nephrol,Necker.Hosp. 10:335-47:335

White DJG. (1981) Cyclosporin A. Cambridge Medicine 1: 29.

Calne RY, Williams R, Lindop M, Farman JV, Tolley ME, Rolles K, MacDougall B,Neuberger J, Wyke RJ, Raftery AT, Duffy TJ, Wight DG, White DJG. (1981) Improvedsurvival after orthotopic liver grafting. BMJ 283: 115-118.

White DJG, Nagao T, Davies H ffS. (1982) The kinetics of post-Cyclosporin A graftacceptance. Transplantation and Clinical Immunology XIII: 21-28. Excerpta Medica,Amsterdam.

Calne RY, Rolles K, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, CraddockGN, Henderson RG, Aziz S, Lewis P. (1980) La Cyclosporine a en transplantationd'organe. Actualities Nephrologiques pp 315-327.

Calne RY, White DJG, Hamilton DV, Thiru S. (1982) Renal function and pathologyduring Cyclosporin A treatment. Transplantation and Clinical Immunology XIII: 41-44. Excerpta Medica, Amsterdam.

White DJG, Calne RY. (1982) Cyclosporin A in heart allografting; Itsimmunosuppressive and tolerance inducing properties. Heart Transplantation 1: 102-109.

Nagao T, White DJG, Calne RY. (1982) Kinetics of unresponsiveness induced by a shortcourse of Cyclosporin A. Transplantation 33: 31-35.

Hamilton DV, Evans DB, Calne RY, White DJG. (1982) Long term nephrotoxicity ofCyclosporin A in transplantation. Dialysis and Transplantation 11: 146.

White DJG, Calne RY. (1982) The use of Cyclosporin A immunosuppression in organgrafting. Immuno Rev 65: 115-31:115.

14

Calne RY, White DJG, Evans DB, Wight C. (1982) Three years' experience withCyclosporin A in clinical cadaveric kidney transplantation. Proceedings of anInternational Conference on Cyclosporin A. Ed DJG White. Elsevier, Amsterdam p 347.

White DJG, Nagao T Davies, H ffS. (1982) Experimental transplantation in smallanimals. Proceedings of an International Conference on Cyclosporin A. Ed DJG White.Elsevier, Amsterdam p 89.

Beveridge T, Wood AJ, Calne RY, White DJG. (1982) Cyclosporin A as soleimmunosuppressive agent in recipients of kidney allografts from cadaver donors.Preliminary results of European Multicentre Trial. Lancet II: 57-60.

White DJG. (1982) Cyclosporin A clinical and therapeutic potential. Drugs 24: 322.

Kasahara K, White DJG., Calne RY. (1982) Antigen dependence of Cyclosporin Ainduced allograft acceptance. Transplantation 34: 216.

Calne RY, White DJG. (1982) The use of Cyclosporin A in clinical organ grafting.Annals of Surgery 196: 330.

Calne RY, White DJG, Rolles K, Duffy TJ, Kass T. (1982) Renal and segmentalpancreatic grafting with draining of exocrine secretion and initial continuous intravenousCyclosporin A in a patient with insulin-dependent diabetes and renal failure.BMJ(Clin.Res.Ed) 285: 677-680.

Kemp E, Jacobsen IA, Frandsen NE, Kristiansen JH, Dieperink H, Madsen CM, NielsenHV, Olsen H, White, DJG, Sindrup E, Faurschou S. (1982) Pancreas transplantation inthe treatment of diabetes mellitus. A review and report of a case. Ugeskr Laeger 144:3071-3075.

White DJG. McNaughton D, Calne RY. (1983) Is monitoring Cyclosporin A serum levelsof clinical value? Transplant Proc XV: 454.

White DJG, Calne RY. (1983) Immunosuppression in liver transplantation. In: LiverTransplantation. Ed RY Calne. Grune & Stratton. Chapter 21, 201.

White DJG. (1983) Cyclosporin A - Clinical applications and Immunology. Clinicsin Immunology and Allergy 3: 287-304.

Merion RM, White DJG, Thiru S, Evans DB, Calne RY. (1983) Cyclosporin A: Fiveyears' experience in human renal transplantation. Turkish J Transplant and Dialysis 1:7-19.

15

White DJG. (1983) Development of new immunosuppressive compounds withCyclosporin A as the example. Transplantation and Clinical Immunology XV: 83-91.Excerpta Medica, Amsterdam.

Beveridge T, Wood AJ, Calne RY, White DJG.. (1983) Cyclosporin in cadaveric renaltransplantation: One-year follow-up of a multicentre trial. Lancet II: 986-989.

White DJG, Davies H ffS, Kamida N, Nagas T. (1983) Potential for Toleranceinduction with Cyclosporine. Transplant Proc 15: 2278-2284.

White DJG, Calne RY. (1984) Chemical Immunosuppression. In: TransplantationImmunology. Ed RY Calne. Oxford University Press pp 254-277.

White DJG, Blatchford NR, Cauwenbergh G. (1984) Cyclosporine and Ketoconazole.Transplantation 37: 214-215.

Merion RM, White DJG, Thiru S, Evans DB, Calne RY. (1984) Five years' experiencewith Cyclosporin A in cadaveric transplantation. New Engl J Med 310: 148-154.

White DJG , Calne RY. (1984) Immunosuppression por Cyclosporina A en al injertode organos. In: Trasplante Renal. Eds A Caralps, JM Gil-vernet. Toray-Barcelona, pp385-396.

Merion RM, White DJG, Calne RY. (1983) Early renal allograft rejection episodes areless aggressive with Cyclosporin A immunosuppression. Transplant Proc 15: 2172-2177.

White DJG. (1984) Pancreas transplantation - hope for the future. Balance 82: 5.

White DJG. (1984) Cyclosporin A and Transplantation. The Pharmaceutical Journal 232:771-772.

Holt DW, White DJG. (1984) How to measure Cyclosporine. Lancet ii: 228.

White DJG. (1984) Interleukins and other non-specific factors involved in the immunesystem. In :Transplantation Immunology. Ed RY Calne. Oxford University Press, pp195-198.

White DJG. (1984) Thoracic Duct Drainage. In :Transplantation Immunology. EdRY Calne. Oxford University Press pp 334-338.

White DJG. (1984) Total lymphoid irradiation. In: Transplantation Immunology. EdRY Calne. Oxford University Press, pp 339-346.

White DJG, Shaw JL. (1985) Immunosuppression. In: Handbook of ExperimentalImmunology. 4th Edition. Ed Wier & Herzenberg. Blackwell Scientific, Chapter 81.

16

Drakopoulos S, White DJG, Merion RM, Winter S, Calne RY. (1985) An assessment ofthe clinical value of monitoring Cyclosporin A plasma levels. Trans Proc 17: 1258.

McNaughton D, White DJG. (1985) Measurement of immune activity in transplantrecipients. Trans Proc 17: 669.

Merion RM, White DJG. (1985) Nephrotoxicity of Cyclosporine. New Engl J Med 312:48.

Hakim M, White DJG, Cory-Pearce R, English TA, Wallwork J. (1985) Is Cyclosporin Anephrotoxicity related to its immunosuppressive effectiveness? Heart Transplantation IV:217-219.

Calne RY, White DJG, Thiru S, Rolles K, Drakopoulos S, Jamieson NV. (1985)Cyclosporin G immunosuppressive effect in dogs with renal allografts. Lancet i: 1342.

White DJG, McNaughton D, Watson, JV. (1985) A cellular analysis of in vitro and invivo activation of lymphocytes in the presence of Cyclosporin A. Trans Proc 18: 595.

White DJG. (1985) Cyclosporin in organ transplantation. Pharmacy International 6: 65.

Land W, Castro LA, White DJG, Hillebrand G, Hammer C, Klare B, Fornara P. (1986)Cyclosporin in renal transplantation. Prog.Allergy 38: 293-328.

White DJG, Winters S. (1986) The use of I125 labelled tracer for monitoring Cyclosporinlevels in transplant recipients. 2nd British Symposium on Cyclosporine. OxfordMedical Education Services, p 12.

Wallwork J, White DJG. (1986) Renal function in cardiac transplant recipients. 2ndBritish Symposium on Cyclosporine. Oxford Medical Education Services, p 70.

Collier SJ, Calne RY, White DJG, Winters S, Thiru S. (1986) Blood levels andnephrotoxicity of Cyclosporin A and G in Rats. Lancet i: 216.

Collier SJ, Calne RY, Thick M, Jamieson NV, De Curtins M, Barroso E, White DJG,Thiru S. (1986) Alternate-day Immunosuppression [letter] Lancet 1: 267-268.

White DJG, Calne RY, Rolles K, McNaughton D, Winter S, Drakopoulos S, Thiru S.(1986) Is Cyclosporin G more or less immunosuppressive than Cyclosporin A? TransProc 18: 1244.

Barroso Da Silva E, Gore SM, White DJG, Bourgeon A, Rolles K, Calne RY. (1986)Risk factors in clinical orthotopic liver transplants. Trans Proc 18: 1210.

17

Harder F, Thiel G, Calne RY, White DJG. (1986) Cyclosporine in cadaver renaltransplantation. Trans Proc 18: 1299.

Jones DK, Hakim M, Wallwork J, White DJG, Higenbottam TW. (1986) Seriousinteraction between Cyclosporin A and Sulphadimidine. British Medical Journal 292:728.

Kemp E, White DJG, Dieperink H, Larsen S, Starklint H, Steinbruchel D. (1986) Delayedrejection of rabbit kidneys transplanted into baby pigs. Trans Proc 19: 1143.

Collier DS, Calne RY, DeCurtins M, Thiru S, White DJG. Jamieson NV, Thick M,Barroso E, (1987) Alternate day Cyclosporine A and Azathioprine in experimental dogrenal allografts. Trans Proc 19: 1279-1280.

McNaughton D, White DJG. (1987) The differential diagnosis of rejection andnephrotoxicity in renal allograft recipients treated with Cyclosporin A. J Med Sci 15:307.

Twentyman PR, Fox NE, White DJG. (1987) Cyclosporin A and its analogues asmodifiers of adriamycin and vincristine resistance in a multi-drug resistant humanlung cancer cell line. Br J Cancer 56: 55-57.

White DJG, Friend P. (1987) Immunosuppression. In: Liver Transplantation. 2nd Ed.Ed R. Calne. Grune & Stratton, p 305.

Gore SM, Barroso E, White DJG. (1987) Risk factors in orthotopic first livertransplantation. In: Liver Transplantation. 2nd Ed. Ed RY Calne. Grune & Stratton p513.

Reding R, White DJG, Wright LS, Davies H ffS, Calne RY. (1987) Successful removalof preformed anti-guinea pig xeno-antibodies in the rat by plasma exchange. E SurgRes 27: 1974.

Lim SM, White DJG, Calne RY. (1987) Identifying a susceptible period followingCyclosporine A induced tolerance of heart grafts in the rat. Trans Proc 19: 4218.

Lim SM, White DJG, Calne RY. (1987) Cyclosporine A induced acceptance of MHCincompatible grafts differs immunologically from class I or minor antigen mismatchedgrafts accepted in the absence of immunosuppression. Trans Proc 19: 4252.

White DJG, Gore SM, Barroso E, Calne RY. (1987) The significance of ABO bloodgroups in liver transplant patients. Trans Proc 19: 4571.

Lim SM, Thiru S, White DJG. (1987) Heterotopic heart transplantation in the ratreceiving FK-506. Trans Proc 19: 68.

18

Collier DS, Calne RY, Friend PJ, Lim SM, White DJG. (1987) FK-506 in experimentalallografts. Trans Proc 19: 3975.

Lim SM, White DJG, Calne RY. (1987) Minor and Class I MHC incompatibilities do notcause rejection of heart grafts but influence the rejection of skin graft. Trans Proc 19:4229.

White DJG. (1988) Immunosuppression for heart and heart-lung transplantation. In :Heart and Heart-lung transplantation. Ed J Wallwork. Grune & Stratton, pp 155-173.

White DJG. (1988) Immunosuppression. In: Immunological Essentials of SurgicalPractice. Ed CH Toledo-Pereyra. PSG, Massachusetts, p 362.

White DJG, Wright L, Rose M, Wallwork J, English TA, Hakins M, Hatten J. (1988)Failure of whole blood Cyclosporine levels to provide a reliable measure ofimmunosuppression in clinical heart and heart/lung transplantation. Trans Proc 20: 422.

Lim SM, White DJG, Calne (1988) Cyclosporine coverage during the risk period leads to100% long-term graft acceptance in the rat. Transplant.Proc. 20:1013.

Lim SM, White DJG, Calne RY. (1988). Unresponsiveness to class I antigens is not equalto tolerance to class I antigens induced by Cyclosporin A. Transplant .Proc. 20:1031

Collier D St J, Calne RY, Thiru S, Friend PJ, Lim SML, White DJG, Kono H, Levickis J.(1988) FK 506 in Experimental Renal allografts in Dogs and Primates. Trans Proc 20:226.

White DJG. (1988) Organ Transplantation and Replacement (Review). Lancet i: 739.

Lim SML, White DJG. (1988) Long term residence of a graft is an insufficient stimulusfor the induction of tolerance. Investigating the role of cyclosporine in class1-disparateheart grafts ub tge rat. Exp Med 168: 807.

White DJG, Lim SM. (1988). The Induction of tolerance by Cyclosporine.Transplantation 46: 118-121.

Lim SML, Da Costa M, White DJG. (1988) Cyclosporine induced suppressor cells arecyclophosphamide resistant. Med Sci Res 16: 1179-1180.

Lim SM, Kono H, White DJG. (1989) Splenectomy abrogates the ability of thoracicduct lymphocytes of tolerant rats to transfer suppression. Trans Proc 21: 480.

Cooper DKC, Kemp E, Reemtsma K, White DJG. (1989) Xenotransplantation.Transplantation 47: 747.

19

Lim SML, White DJG. (1989) Cyclosporin A and tolerance induction in experimentalanimals. In: Cyclosporin: mode of action and clinical application. Ed A Thomson.Kluwer, London, pp 82-111.

Reding R, Davies HS, White DJG, Wright LJ, Marbaix E, Alexandre GP, Squifflet JP,Calne RY. (1989) Effect of plasma exchange on guinea pig to rat heart xenograft. TransProc. 21, 534.

Reding R, White DJG, Davies H ffS, Latinne D, Delepaut B, Lambotte L, AlexandreGPJ, Squifflet JP, Calne RY. (1989) Failure of splenectomy to affect the antibodyrebound after plasma exchange in the rat. Trans Proc 21: 779.

Reding R, White DJG, Wright LJ, Davies H ffS, Alexandre GPJ, Squifflet JP, Calne RY.(1989) Qualitative analysis of antibody rebound after plasma exchange in the rat. TransProc 21: 777.

Drakopoulos S, White DJG, Calne RY, Wreghitt TG, Walker JR, Taylor CED. (1989)Antibody responses to certain viruses by Cyclosporine immunosuppressed recipients.Nephrological Chronicles 5: 429.

Katami M, Madden PW, White DJG, Watson PG, Kamada N. (1989) The extent ofimmunological privilege of orthotopic corneal grafts in the inbred rat. Transplantation 48:371-376.

Lim SM, White DJG. (1989) A requirement for continued graft presence in themaintenance of systemic tolerance induced by cyclosporin A in rats. Trans Int 2: 13.

Lim SM, White DJG. (1989) The induction of allograft tolerance in immune rats.Transplantation 47:915

Reding R, White DJG, Davies HS, Latinne D, Delepaut B, Lambotte L, Calne R. (1989)Effect of splenectomy on antibody rebound after plasma exchange. Transplantation48:145

Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DGJ, Thiru S. (1989)Rapamycin for immunosuppression in organ allografting. Lancet 2:227

Katami M, White DJG, Watson PG. (1989) An analysis of corneal graft rejection in therat. Trans Proc 21: 3147-3149.

Collier DS, Calne RY, Lim S, Pollard SG, White DJG, Thiru S. Barron P, Da Costa D.(1989) Rapamycin in experimental renal allografts in dogs and pigs. Trans Proc 22:1674.

20

Katami M, Lim SML, Kamada N, Davies H, Butcher GW, White DJG, Watson PG,Calne RY. (1990) A pure Class II MHC disparity does not induce rejection of cornea orheart grafts. Trans Proc 22: 2200-2202.

van den Bogaerde, White DJG, Roser B, Kampinga J, Aspinall R. (1990) In vitro and invivo effects of monoclonal antibodies against T cell subsets on allogeneic and xenogeneicresponses in the rat. Transplantation 50:915

Lim SM, Kogure K, White DJG. (1990) Steroid treatment depresses the production of transplantation tolerance. Trans Proc 22: 1989.

White DJG, Obers A. (1990) The significance of tumour necrosis factor serum levels inorgan transplantation. Eur.Cytokine.Netw.1:245

White DJG, Gilks WK. (1990) MHC restricted self tolerance: The difference betweenacute and chronic rejection. Transplantation and Clin Immunol 21: 135.

White DJG, Obers A. (1990) Tumour Necrosis Factor in Organ Transplantation. AnnalsAcad Med 19: 142.

White DJG. (1990) When Surgeons Experiment. Lancet i: 335.

White DJG, Obers A. (1990) Tumour Necrosis factor in organ transplantation. AnnalsAcad Med 19: 142

White DJG. (1990) Organ transplantation: Current clinical and immunological concepts.Lancet i: 629-630.

Lim SM, Wee A, Chong, White DJG. (1990) An analysis of concordant xenograftrejection in the nude rat model. Trans Proc 22: 2095-2097.

Lim SM, Kogure M, White DJG. (1990) Cyclosporin A-induced tolerance is notamplified by the addition of steroid therapy. Trans Int 3: 70-73.

Van den Bogaerde J, White DJG, Roser B, Kampinga JR, Aspinall R. (1990) In Vitroand in vivo subsets in allogeneic and xenogeneic responses in the rat. Transplantation 50:915-920.

Lim SML, White DJG. (1991) The Pharmacology of Immunosuppression. Annals AcadMed 20: 144-149.

White DJG, Obers A. (1991) Measurement of TNF serum levels in OrganTransplantation. Eur Cytokine Net 1: 147-153.

21

Van den Bogaerde JB, White DJG, Mieny CJ. (1991) A look at the future of inter-speciesorgan transplantation SA Med J 80: 538-541.

White DJG. (1991) Pharmacological immunoregulation in transplantation and auto-immunity. In: Clinical Immunology. Eds Roitt and Brostoff. Gower, pp 1-27.

Johnston PS, Lim SM, Wang MW, Wright L, White DJG. (1991) Hyperacute Rejectionof xenografts in the complete absence of antibody. Trans Proc 23:877-879.

Van den Bogaerde J, Aspinall R, White DJG, Howard JC. (1991) Xenogeneic responsesin the syrian hamster. 1) evidence for a normal T cell repertoire. Int Immunol 3: 49-56.

Lim SML, Li SQ, Wee A, Chong SM, Hu C, Rauff A, White DJG. (1991) Bothconcordant and discordant heart xenografts are rejected by athymic (nude) rats with thesame tempo as in T cell competent animals. Trans Proc 23: 581-582.

Oglesby TJ, White DJG, Tedja I, Liszewski MK, Wright L, Van den Bogaerde J,Atkinson JP. (1991) Protection of mammalian cells from complement-mediated lysis bytransfection of human membrane co factor protein and decay accelerating factor.Transactions Assoc American Physicians CIV: 164-172.

Katami M, Graudenz MS, White DJG, Watson PG. (1991) The role of antigen presentingcells in rat corneal graft rejection. Trans Proc 23: 93-96.

Forty J, Metcalfe M, White DJG, Wallwork J. (1991) The development and use of an exvivo heart model to study hyperacute xenograft rejection. Minerva Chirurgica 46: 123-127

White DJG (1991) FK 506: The promise and the paradox [editorial ]Clin Exp Immunol83: 1-3.

van den Bogaerde J , Aspinall R, Wang MW, Cary N, Lim SM, Wright L, White DJG.(1991) Induction of long-term survival of hamster heart xenografts in rat.Transplantation 52: 15-20.

van den Bogaerde JB, Aspinall R, White DJG, (1991) Hamster to rat xenografts are notrejected primarily by rat T cells. Transplant.Proc. 23:2277

White DJG, Van den Borgarde J, Lim SM. (1991) The immunology ofxenotransplantation. Ann.Acad.Med.Singapore 20:770

Van den Bogaerde J, White DJG. (1991) Immunosuppression in xenotransplantation. In:Xenotransplantation. Eds Cooper DKC, Kemp E, Reemtsma K, White DJG. Springer-Verlag, pp 161-179.

22

Lim SML, Li Sq, Wee A, Chang SM, H C, Rauff A, White DJG. (1991) Both Concordantand Discordant Heart Xenografts are Rejected by Athymic (Nude) Rats with the SameTempo as in T Cell Competent Animals. Trans Proc 23: 581-582.

Atkinson JP, Oglesby TJ, White DJG, Adams EA, Liszewski MK. (1991) Separation ofself from non self in the complement system. A role for membrane co factor protein anddecay accelerating factor. Clin Exp Immunol 86: (1) 27-30.

Wang MW, Wright LJ, Sims MJ, White DJG. (1991) Presence of human chromosome 1with expression of human decay-accelerating factor (DAF) prevents lysis ofmouse/human hybrid cells by human complement. Scan J Immunol 34: 771-778.

Forty J, Metcalfe M, White DJG, Wallwork J. (1991) The development and use of an ex-vivo heart model to study hyperacute xenograft rejection. Minerva Chirurgica 46: 123-127.

Forty J, Hasan R, Cary N, White DJG, Wallwork J. (1992) Perfusion of rabbit heartswith human blood results in immediate graft thrombosis, which is temporally distinctfrom hyperacute rejection. Trans Int 24: 610-611.

White DJG, Oglesby T, Liszewski MK, Tedja I, Hourcade D, Wang M-W, Wright L,Wallwork J, Atkinson JP. (1992) Expression of human decay accelerating factor ormembrane cofactor protein genes on mouse cells inhibits lysis by human complement.Trans Proc 24: 474-476.

Forty J, Hasan R, Cary N, White DJG, Wallwork J. (1992) Hyperacute rejection of rabbithearts by human blood is mediated by the alternative pathway of complement. TransProc 24: 488-489.

Hasan RI, van den Bogaerde J, Forty J, Wright L, Wallwork J, White DJG. (1992)Prolonged survival of hamster to rat heart xenografts with cyclophosphamide therapy.Trans Proc 24: 517-518.

Hasan R, van den Bogaerde J, Forty J, Wright L, Wallwork J, White DJG. (1992)Xenograft adaptation is dependent on the presence of antispecies antibody, not prolongedresidence in the recipient. Trans Proc 24: 531-532.

van den Bogaerde J, Hasan R, White DJG. (1992) An analysis of concordantxenografting. Trans Proc 24: 513-514.

Wang MW, Johnston PS, Wright LJ, Lim SML, White DJG. (1992) Immunofluorescentlocalization of pig complement component 3 regardless of the presence or absence ofdetectable immunoglobulins in hyperacutely rejected heart xenografts. Histochemical J24: 102-109.

23

Hasan R, van den Bogaerde JB, Wallwork J, White DJG. (1992) Evidence that long-term survival of concordant xenografts is achieved by inhibition of anti-species antibodyproduction. Transplantation 54: 408-413.

Forty J, Hasan R, Cary N, Wallwork J, White DJG. (1992) Perfusion of rabbit heartswith human blood results in immediate graft thrombosis which is temporarily distinctfrom hyperacute rejection Transplant.Proc. 24:610

Hasan R, Van den Bogaerde J, Forty J, Wright L, Wallwork J, White DJG. (1992)Inhibition of rejection of hamster to rat heart xenografts. Trans Int 5: 313-317.

White DJG, Oglesby TJ, Tedja I, Lisezwski K, Wallwork J, Wang M-W, Atkinson JP.(1992). Expression of human decay accelerating factor or membrane co factor proteingenes on mouse cells inhibits lysis by human complement Trans Int 5: 648-650.

White DJG, Oglesby T, Liszewski MK, Tedja I, Hourcade D, Wang M-W, Wright L,Wallwork J, Atkinson JP (1992) Expression of hDAF or membrane cofactor proteingenes on mouse cells inhibits lysis by human complement. Transplant Proc 24: (2) 474-476

White DJG. (1992) Transplantation of Organs between species. Int Arch AllergyImmunol 98: 1-5.

White DJG, van den Bogaerde J, Lim SML. (1992) The Immunology ofXenotransplantation. Annals Acad Med 20: 770-776.

Katami M, White DJG, Watson PG. (1992) Site-specific immunosuppression for cornealgraft survival in the rat. Trans Proc 24: 1406-1408.

Johnston PS, Wang MW, Lim SML, Wright LJ, White DJG. (1992) Discordantxenograft rejection in an antibody free model. Transplantation 54: 573-576.

Forty J, White DJG, Wallwork J. (1993) Activation of the alternative pathway ofcomplement in hyperacute xenograft rejection of rabbit hearts by human blood. J HeartLung Transplant 12: 283-287.

Hasan RI, Sriwatanawongsa V, Wallwork J, White DJG. (1993) Consistent prolonged"concordant" survival of hamster to rat cardiac xenografts by inhibition of anti-speciesantibodies with Methotrexate. Trans Proc 25: 421-422.

Oglesby TJ, Allen CJ, Liszewski MK, Atkinson JP White DJG,. (1992) MembraneCofactor Protein (MCP, CD46) protects cells from complement-mediated attack by anintrinsic mechanism. J Exp Med 175: 1547-1551.

White DJG . (1993) Xenotransplantation. In: Clinical and Experimental Perspectives inSandimmun Therapy 3: 29-32.

24

Cary N, Moody J, Yannoutsos N, Wallwork J, White DJG. (1993) Tissue expression ofHuman Decay Accelerating Factor (DAF), a regulator of complement activationexpressed in mice. A potential approach to inhibition of hyperacute xenograft rejection.Trans Proc 25: 400-401.

White DJG. (1993) Cardiac Xenotransplantation. Annual of Cardiac Surgery 6: 167-172.

White DJG. (1993) Too much of a good thing. Mercuritus Pragmaticus 62: 10-12.

Braidley P, Dunning J, White DJG, Wallwork J. (1993) Xenotransplantation. Surgery 8:477-480.

White DJG. (1993) Immunosuppression for heart transplantation. Br J Biomed Sci 50:277-283.

Sriwatanawongsa V, Davies HS, Brons IG, White DJG, Jamieson NV, Calne RY. (1993)Conditions required for donor passenger leukocytes in the induction of tolerance by ratliver grafts Transplant.Proc. 25:2855

Forty J, White DJG, Wallwork J. (1993) A technique for perfusion of an isolatedworking heart to investigate hyperacute discordant xenograft rejection. J ThoracicCardiovasc Surg 1062: (2) 308-316.

Pierson RN, White DJG, Wallwork J. (1993) Ethical considerations in clinical cardiacxenografting [letter; comment] J Heart Lung Transplant 12: 876-877.

Kemp E, Disperink H, Leth P, Jensenius JC, Nielsen B, Lillevang ST, Salomon S,Steinbruchel D, Larsen S, Koch C, White DJG. (1994) Monoclonal antibodies tocomplement C3 prolong survival of discordant xenografts. Guinea pig heart to rattransplantation. Trans Proc 26: 1011-1115.

Dunning J, Braidley PC, Wallwork J, White DJG. (1994) An analysis of hyperacuterejection of pig hearts by human blood using an ex-vivo perfusion model. Trans Proc 26:1016-1017.

Braidley PC, Dunning JJ, Wallwork J, White DJG. (1994) Xenograft rejection in theGuinea-pig. Trans Proc 26: 1018-1019.

White DJG. (1993) Immunosuppression in liver transplantation. In: LiverTransplantation. Ed Neuberger J, pp 230-237.

White DJG., Wallwork J. (1993) Xenografting: Probability, possibility or pipe dream?[see comments] Lancet 342: 879 – 881.

25

White DJG, Gilks W (1993) The ontogeny of immune responses. J.Heart LungTransplant 12:S301

Forty J, White DJG, Wallwork J. (1993) Activation of the Alternative Pathway ofComplement in Hyperacute Xenograft Rejection of Rabbit Hearts by Human Blood. JHeart Lung Transplant 12: 283-287.

White DJG, Cozzi E, Langford G, Oglesby T, Wang M-W, Wright L, Wallwork J. (1994)Controle du rejet hyperagu de xenogreffe par la modification genetique du donneur. DansActualities Nephrologiques. Eds Kriess H, Grunfeld JP. Medicine-Sciences FlammarionParis, pp 307-317

Hasan RI, White DJG. (1994) Modification of Heron's technique for heterotopic cardiactransplantation in rats. J Thoracic Cardiovasc Surg 107: 1168-1169.

Braidley P, White DJG. (1994) Concordant organ xenotransplantation. Xeno 2: 25-30.

Langford GA, Yannoutsos N, Cozzi E, Lancaster R, Elsome K, Chen P, Richards A,White DJG. (1994) Production of pigs transgenic for Human Decay Accelerating Factor.Trans Proc 26: 1400-1401.

Cozzi E, Langford GA, Richards A, Elsome K, Lancaster R, Chen P, Yannoutsos N,White DJG. (1994) Expression of Human Decay Accelerating Factor in transgenic pigsTrans Proc 26: 1402-1403.

Braidley PC, Dunning JJ, Wallwork J, White DJG. (1994) Prolongation of survival of ratheart xenografts in C3 deficient Guinea Pigs. Trans Proc 26: 1259-1261.

Braidley PC, Dunning JJ, Wallwork J, White DJG. (1994) Phylogenetic disparity doesnot always equate with hyperacute rejection in xenotransplantation. Trans Proc 26: 1230-1231.

Mieny CJ, Karusseit VOL, Van den Bogaerde JB, Hasan RIR, White DJG. (1994)Prolongation of survival of heterotopic heart xenografts by antibody and complementsuppression in primates Trans Proc 26 1073-1074.

Hunt BJ, Dunning JJ, Segal H, Parratt R, White DJG, Wallwork J. (1994) Pig-to-humanxenograft reaction: is haemostatic activation dependent on the presence of anti-pigantibodies or complement Transplant.Proc. 26:1156

Dunning JJ, White DJG, Wallwork J (1994) Transgenic pigs as potential donors forxenografts. Rejection and Tolerance Ed. Touraine JL. Kluwer Academic Press TheNetherlands pp 149-160

White DJG (1994) Heart Transplantation – Pig hearts with human genes. CorEuropaeum 3:(2) 80

26

White DJG, Cozzi E, Langford G, Oglesby T, Wang M-W, Wright L, Wallwork J (1994)Genetic engineering of the pig to provide organ and tissue xenografts for man. OrganBiology Vol 1: 21-29

White DJG. (1994) Xenografting: Present and future. Xeno 2: (1) 1-2

Mieny CJ, Karrusseit VO, van den Bogaerde, Hasan RI, White DJG, (1994) Prolongationof survival of heterotopic heart xenografts by antibody and complement suppression inprimates Transplant. Proc 26:1073

Pierson RN, Tew DN, Konig, Dunning, White DJG, Wallwork J. (1994) Pig lungs aresusceptible to hyperacute rejection by human blood in a working ex vivo heart-lungmodel Transplant.Proc 26:1318

Hasan RI, Sriwatanawangosa V, Wallwork J, White DJG. (1994) Graft adaptation inhamster-to-rat cardiac xenografts. Trans Proc 26: 1282-1283.

Pierson RN, Tew DN, Konig WK, Dunning JJ, White DJG., Wallwork J. (1994) Piglungs are susceptible to hyperacute rejection by human blood in a working ex-vivo heart-lung model. Trans Proc 26: 1318-1319.

Pierson RN, Dunning JJ, Konig WK, Tew DN, Braidley PC, Wallwork J, White DJG.(1994) Mechanisms governing the pace and character of pig heart-lung rejection byhuman blood. Trans Proc 26: 2337-2338.

Schuurman H-J, Joergensen J, Kuipers H, Meerloo T, Lardelli P, Heistand DH, WhiteDJG., Schrier MH. (1994) Vascular transplantation of Syrian hamster heart into Lewisrat: Effect of Brequinar, Cyclosporine, Cobra Venom Factor and splenectomy. Trans Proc26: 1217-1219.

White DJG. (1994) The Way Ahead in Transplantation. National Kidney FederationPapers from 15th Annual Patients' Conference.

Dunning JJ, White DJG (1994) A comparison of the performance of pig hearts perfusedwith pig or human blood using an ex-vivo working heart model. Euro. J. Cardiothorac.Surg. 8: 204-206

Dunning JJ, White DJG, Wallwork J. (1994) The rationale for xenotransplantation as asolution to the donor organ shortage. Pathol.Biol. (Paris.) 42:231

White DJG, Cozzi E, Langford G, Oglesby T, Wang MW, Wright L, Wallwork J.(1995) Genetic engineering of the donor species to control hyperacute xenograftrejection. Adv.Nephrol.Necker.Hosp. 24: 331-40:331.

Dunning JJ, White DJG, Wallwork J (1995) ////the xenograft: its current status and thefuture prospects Rev.Esp.Cardiol. 48 Suppl 7:145-8:145

27

Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. (1995)Endothelial expression of human complement inhibitor Decay Accelerating Factor intransgenic pigs - A potential approach for preventing xenograft rejection. Transplant 59:1325-1333.

Carrington CA, Richards AC, Cozzi E, Langford G, Yannoutsos N, White DJG. (1995)Expression of human DAF on Pig endothelial cells protects from human complement.Trans Proc 27: 321-323.

Lancater RT, Elsome KE, Yannoutsos N, Langford GA, Richards R, Cozzi E, Tolan M,Wallwork J, White DJG. (1995) Production of pigs transgenic for human regulators ofcomplement activation. Trans Proc 27 (1) 324-325

Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. (1995)Tissue expression of human complement inhibitor, DAF, in Transgenic pigs – A potentialapproach for preventing xenograft rejection. Transplantation 59: 1325-1333

Young VK, Konig WK, Tew DN, Wallwork J, White DJG, Pierson RN. (1995) WhiteBlood Cells and Platelets are Integral to the Hyperacute Rejection of the Pig Heart byHuman Blood. Trans Proc 27:272

Pierson RN, Kaspar-Konig W, Tew DN, Young VK, Braidley PC, White DJ, Wallwork J.(1995) Profound pulmonary hypertension characteristic of pig lung rejection by humanblood is mediated by xenoreactive antibody independent of complement. Transplant.Proc.27:274

White DJG, Langford GA, Cozzi E, Young VK. (1995) Production of pigs transgenicfor human DAF. A strategy for Xenotransplantation. Xenotransplant 2: 213-217.

Chavez-Cartaya R, Cozzi E, Pino-Desola G, Jamieson NV, White DJG. (1995)Regulation of Complement Activation in Rat Liver Ischemia and Reperfusion:Expression of Endothelial CD59 (RIP). Trans Proc 27: (5) 2852-2854.

Cozzi E, White DJG. (1995) The Generation of Transgenic Pigs as Potential OrganDonors for Humans. Nature Med: 1 (9) 964-966.

Tolan M, Cozzi E, Braidley P, White DJG, Wallwork J. (1995) Xenotransplantation: Theuse of transgenic pig organs for human transplantation. UKTSSA Bulletin (Autumn).

Carrington CA, Cozzi E, Langford GA, Richards AC, Rosengard A, Yannoutsos N,White DJG. (1995) Transgenic Pigs and Xenotransplantation. In: Organ Shortage: TheSolutions. Eds: Touraine JL et al. Kluwer Academic Publishers, NL, pp 309-316.

28

White DJG. (1995) Xenotransplantation. In: Transplantation '95. The Outlook forTransplantation towards 2000. ICSS Series 211. Ed: RW Johnson. RSM, London, pp35-39.

Cozzi E, Langford GA, Wright L, Tucker A, Yannoutsos N, Richards A, Rosengard A,Elsome K, Lancaster R, White DJG. (1995) Comparative Analysis of Human DAFExpression in the Tissues of Transgenic Pigs and Man. Trans Proc 27: 319-320.

Braidley PC, Wallwork J, White DJG. (1995) Prolonged Survival of Cardiac XenograftsBetween Widely Divergent Species: Bird to Mammal. Trans Proc 27: 307-308.

White DJG , Cozzi E. (1995) Il Maiale del prossimo milennio. Trapianti 8: 30-33.

White DJG, Langford GA, Cozzi E, Young VJ. (1995) Protective Effects of human DAFin Transgenic Pigs. Xeno 3: (3) 48-51.

Chavez-Cartaya RE, Pino DeSola G, Wright L, Jamieson NV, White DJG. (1995)Regulation of the Complement Cascade by Soluble Complement Receptor Type 1.Protective Effect in Experimental Liver Ischemia and Reperfusion. Transplantation 59:1047-1052.

Yannoutsos N, Ijzermans JNM, White DJG, Grosveld F. (1995) Using yeast artificialchromosomes to generate transgenic animals. Xeno 3: 107-109.

White DJG. (1995) Aversion to Xenotransplantation. Nature 378: 434 [Letter] [seecomments].

Dunning JJ, Wallwork J, White DJG (1995) The Xenograft its current status and thefuture prospects Rev.Esp.Cardiol 48 Suppl 7:145-8:145

Rosengard AM, Cary N, Horsley J, Belcher C, Langford G, Cozzi E, Wallwork J, WhiteDJG, (1995) Endothelial expression of human decay accelerating factor in transgenic pigtissue: a potential approach for human complement inactivation in discordant xenografts.Transplant.Proc. 27:326

White DJG. (1996) Alteration of Complement Activity: a Strategy forXenotransplantation. Trends in Biotechnology 14: 3-5.

Carrington CA, Richards AC, Tucker AW, Peters AL, White DJG. (1996) A line oftransgenic pigs in which the expression of human decay-accelerating factor byendothelial cells is increased in the presence of inflammatory stimuli.Xenotransplantation 3: 87-91.

Robson SC, Young VK, Cook NS, Kottirsch G, Siegel JB, Lesnikosi BA, Candinas D,White DJG, Bach FH. (1996) Inhibition of platelet GPIIbIIa in an ex vivo model does notprolong cardiac survival time. Xenotransplantation 3:43-52.

29

White DJG, Yannoutsos N. (1996) Production of pigs transgenic for human DAF toovercome complement-mediated hyperacute xenograft rejection in man. Res.Immunol147: 88-94.

Robson S, Young VK, Cook NS, Metternich R, Kasper-Konig W, Lesnikoski BA,Pierson RN, Hancock WW, Candinas D, White DJG, Bach FH. (1996) ThrombinInhibition in an ex vivo model of porcine heart xenograft hyperacute rejection.Transplantation 61: 862-868.

Kobayashi T, Taniguchi S, Ye Y, Niekrasz M, Kosanke S, Neethling FA, Wright LJ,Rose AG, White DJG, Cooper DK, (1996) Delayed xenograft rejection in C3-depleteddiscordant (pig-to-baboon) cardiac xenografts treated with cobra venom factor.Transplant.Proc. 28:560

White DJG, Langford GA, Cozzi E, Young VJ. (1996) Prevencion de los efectos lesivosdel complemento mediante ingenieria genetica. In: Xenotransplante. Eds M Arias, MGomez-Fleitas, ALM De Francisco. Sandoz, Barcelona. Ch 12: 127-134.

Richards AR, Tucker AW, Carrington CA, White DJG. (1996) Reduced HumanNeutrophil Adhesion to Porcine Endothelia Expressing Human Decay AcceleratingFactor. Trans Proc 28: 636.

Chatterjee M, Watson PG, Cozzi E, Chavez, White DJG. (1996) Success in guinea pig torat orthotopic corneal xenotransplantation with Cyclosporin A. Transplant.Proc.28:731

Pierson RN, Conary JT, Langford G, White DJG, Brigham KL, Parker Re. (1996)Targeted in vivo gene transfection modulated hyperacute rejection of pig lungs perfusedwith human blood. Transplant.Proc. 28:763

Schmoeckel M, Nollert G, Shahmohammadi M, Young VK, Knig W, White DJG,Hammer C, Reichart B, (1996) Human decay accelerating factor successfully protects pighearts from hyperacute rejection by human blood. Transplant.Proc 28:768

Yannoutsos N, Ijzermans JNM, Harkes C, Bonthuis F, Zhou CY, White D, MarquetRLM, Grosveld F. (1996) A Membrane Cofactor Protein transgenic mouse model for thestudy of Discordant Xenograft Rejection. Genes to Cells 1: 409-419.

Tucker AW, Davies H ff, Carrington CA, Richards AC, Elsome K, White DJG. (1996)The Fertility and Breeding Potential of Boars Expressing a functional regulator of humancomplement activation. Trans Proc 28: 652.

Schmoeckel M, Nollert G, Shahmohammedi M, Young VK, Chavez G, Kaspar-Konig W,White DJG, Muller-Hocker J, Arendt RM, Wilbert-Lampen U, Hammer C, Reichart B.(1996) Prevention of Hyperacute Rejection by Human Decay Accelerating Factor inXenogeneic Perfused Working Hearts. Transplantation 62: 729-734.

30

Braidley P, Aravot D, Hunter S, Dunning J, White DJG, Wallwork J, (1996) Transgenicpigs-breakthrough in xenotransplantation Isr.J.Med.Sci 32:795

Taniguchi S, Kobayashi T, Neethling FA, Ye Y, Niekrasz M, White DJG, Cooper DKC.(1996) Cobra Venom Factor Stimulates Anti-alpha-Galactose Antibody Production inBaboons. Implications for pig-to-human xenotransplantation. Transplantation 62: 678-681.

Carrington CA, Tucker AW, Richards AC, White DJG. (1996) Up-regulation of humanDecay Accelerating Factor on Cultured Endothelium From Transgenic Pigs in Responseto Inflammatory Stimuli. Trans Proc 28: 586.

Kuipers HW, White DJG, Daha MR. (1996) Fluorescence In Situ Hybridisation toAnalysis DAF Transgenic Jigsaw Pigs. Trans Proc 28: 639-640.

Pascher A, Pohlein C, Storck M, Abendroth D, Muller-Hocker J, Konig W, Young VK,White DJG, Hammer C. (1996) Expression of human decay accelerating factor (hDAF) intransgenic pigs regulates complement activation during ex-vivo liver perfusion -immunopathological findings. Trans Int 9: (1) 385-387.

Pohlein C, Pascher A, Storck M, Young VK, Konig W, Abendroth D, Wick M, Thiery J,White DJG, Hammer C. (1996) The function of transgenic human DAF-expressingporcine livers during hemoperfusion with human blood. Trans Int 9 Suppl 1:S 392-6:S392.

Storck M, Abendroth D, Prestel R, Pino-Chavez G, Pohlein C, Pascher A, Young V,White DJG, Hammer C. (1996) Role of human decay accelerating factor expression onporcine kidneys during xenogeneic ex-vivo hemoperfusion. Trans Proc 28: 587-588.

Pohlein C, Pascher A, Storck M, Young VK, Konig W, Abendroth D, Wick M, Thiery J,White DJG, Hammer C. (1996) Transgenic human DAF-expressing porcine livers: theirfunction during hemoperfusion with human blood. Trans Proc 28: 770-771.

Pohlein C, Pascher A, Baumann P, Abendroth D, Jochum M, White DJG, Hammer C.(1996) Transgenic porcine livers reduce liberation of humoral mediators duringxenoperfusion with human blood. Transplant.Proc 28:772

Pascher A, Pohelin C, Storck M, Abendroth D, Muller-Hocker J, Young VK, Konig W,White DJG, Hammer C. (1996) Human decay accelerating factor expressed onendothelial cells of transgenic pig affects complement activation in an ex vivo leverperfusion model. Trans Proc 28: 754-755.

White DJG, Calne RYC. (1996) Xenotransplantation. Der Chirurg, 67:324-330.

31

Cozzi E, Langford GA, Wright L, Pino-chavez G, Levy A, Chatterjee M, Yannoutsos N,Miller N, Lancaster R, White DJG. (1996) Longitudinal Analysis of the Expression ofHuman Decay Accelerating Factor on Peripheral Blood Mononuclear Cells and in thePlasma of Transgenic Pigs. Trans Proc 28: 860-861.

Langford GA, Cozzi E, Yannoutsos N, Lancaster R, Elsome K, Chen P, White DJG.(1996) Production of Pigs Transgenic for Human Regulators of Complement Using YACTechnology. Trans Proc 28: 862-863.

White DJG, Yannoutsos N. (1996) Production of pigs transgenic for human DAF toovercome complement-mediated hyperacute xenograft rejection in man. In: CurrentTopics in Complement Research, pp 88-94.

White DJG. (1996) hDAF transgenic pig organs: are they concordant for humantransplantation? Xeno 4: 50-54.

Richards AC, Tucker AW, Carrington CA, White DJG, Wallwork JD. (1996) Neutrophilsand xenotransplantation. Lancet 348: 1596 (Letter).

Cozzi E, Langford GA, Pino-Chavez G, Wright L, Levy A, Miller N, Davies H ffS,Chatterjee M, Lancaster R, Tolan MJ, White DJG. (1996) Longitudinal analysis of theexpression of human decay accelerating factor (HDAF) on lymphocytes, in the plasma,and in the skin biopsies of transgenic pigs. Xenotransplantation 3: 128-133.

Cozzi E, White DJG. (1996) Producing transgenic pigs for organ transplantation intohumans. Biological Sciences 9: 23-25.

Cozzi E, White DJG. (1996) Xenotransplantation. Current Opinion in Nephrology andHypertension 5: 514-516.

White DJG. (1996) Xenotransplantation - a solution to the organ donor crisis? BKPAAnnual Report.

Pierson RN, Pino-Chavez G, Young Vk, Kaspar-Konig W, White DJG, Wallwork J(1997) Expression of human decay accelerating factor may protect pig lung fromhyperacute rejection by human blood. J.Heart Lung transplant. 16:231

Storck M, Abendroth D, Prestel R, Pina-Chavez G, Miller-Hocker J, White DJG,Hammer C. (1997) Morphology of hDAF (CD55) transgenic pig kidneys following exvivo hemoperfusion with human blood. Transplantation 63: 304-310.

Cozzi E, Yannoutsos N, Langford GA, Pino-Chavez G, Wallwork J, White DJG. (1997)Effect of Transgenic Expression of Human Decay-Acclerating Factor on the Inhibition ofHyperacute Rejection of Pig Organs. In: Xenotransplantation: The Transplantation ofOrgans and Tissues Between Species (2nd Ed). Eds: Cooper DKC, Kemp E, Platt JL,White DJG. Springer-Verlag, Berlin.

32

Carrington CA, Richards AC, Peters AL, White DJG. (1997) Novel Responses byTransgenic Pig Endothelial Cells to Simulation by Human Cytokines in terms of h-DAF,E-Selectin and Major Histocompatibility Complex Class II Expression. Trans Proc 29:887.

Tucker AW, Carrington CA, Richards AC, Robson SC, White DJG. (1997) Endothelialcells from hDAF Transgenic Pigs are Protected Against Complement Mediated TissueFactor Expression in vitro. Trans Proc 29: 888.

Pascher A, Pohlein C, Storck M, Prestel R, Mueller-Hoeker J, White DJG, Abendroth D,Hammer C (1997) Immunopathological observations after xenogeneic liver perfusionsusing donor pigs Transgenic for hDAF. Transplantation 63: 384-391

Warner RG, Waterworth P, Cozzi E, Tang K, Davies H, Dunning J, White DJG (1997)Anti-Gala1, 3Gal antibody responses in cynomolgus monkey recipients of transgenic pighearts. New Dimensions in Transplantation.

Watkins NJ, Braidley P, Bray C, Savill CM, White DJG (1997) Coating of hDAF ontomedical devices to improve biocompatibility. Immunopharmocology 38: 111-118

Waterworth PD, Cozzi E, Tolan MJ, Langford G, Braidley P, Chavez G, Dunning J,Wallwork J, White DJG. (1997) Pig-to-primate cardiac xenotransplantation andCyclophosphamide therapy. Trans Proc 29: 899-900.

Mandel TE, Koulmanda M, Cozzi E, Waterworth P, Tolan M, Langford G, White DJG.(1997) Transplantation of Normal and DAF-Transgenic Fetal Pig Pancreas IntoCynomolgus Monkeys. Trans Proc 29: 940.

Schmoeckel M, Nollert G, Shahmohammadi M, Muller-Hocker J, Young VK, Kasper-Konig W, White DJG, Hammer C, Reichart B. (1997) Transgenic Human DecayAccelerating Factor makes Normal Pig Function as a Concordant Species. J Heart &Lung Trans 16:758-764.

White DJG, Schmoeckel M, Cozzi E, Chavez G, Langford G. (1997) Production parGenie Genetique le Porcs pour la Realisation de Xenogreffes Cardiaques. BioDrugs 8:(Suppl 1) 33-36.

Pierson RN, Kaspar-Konig W, Tew DN, Young VK, Dunning JJ, Horsley J, Cary NRB,Wallwork J, White DJG. (1997) Hyperacute Lung Rejection in a Pig-to-HumanTransplant Model. The role of anti-pig antibody and complement. Transplantation 63:594-603.

Soin AS, Pino-Chavez G, Chavez-Cartaya R, Jamieson NV, White DJG, Friend PJ.(1997) Complement activation during rejection in experimental intestinal transplantation.Transplant.Proc. 29:1811

33

Kuipers HW, Langford GA, White DJG. (1997) Analysis of Transgene Integration Sitesin Transgenic Pigs by Fluorescence In Situ Hybridisation. Transgenic Res 6: 253-259.

White DJG (1997) Xenotransplantation Scientific aspects Trans Proc 29: 2727-2728

Carrington CA, Richards AC, Tucker AW, White DJG, van den Bogaerde J. (1997)Complement activation, its consequences and blockade by gene transfer. In: WorldJourney of Surgery: Evolving status of Xenotransplantation. Ed: R Tompkins. Springer21: 907-912.

Watkins NJ, Braidley P, Bray CJ, Savill CM, White DJG. (1997) Coating of humandecay accelerating factor (hDAF) onto medical devices to improve biocompatibility.Immunopharmacology 38: 111-118.

Schmoeckel M, Bhatti FNK, Zaidi A, Cozzi E, Chavez G, Dunning JJ, Wallwork J,White DJG. (1997) Xenotransplantation of pig organs transgenic for hDAF - An Update.Trans Proc 29: 3157-3158.

White DJG. (1997) Can xenotransplantation from transgenic pigs solve the organshortage crisis? In: Anaesthesia and Intensive Care for Organ Transplantation. Eds JRKlink, MJ Lindop. Chapman & Hall, London.

White DJG. (1997) Xenotransplantation - A solution to the Donor Organ Shortage. In:Organ and Tissue Donation for Transplantation. Eds J Chapman, M Deierhoi, C Wight.Edward Arnold, London.

Cozzi E, Tucker AW, Langford GA, Pino-Chavez G, Wright L, O’Connell MJ, YoungVJ, Lancaster R, McLaughlin, Hunt K, Bordin MC, White DJG. (1997) Characterizationof pigs transgenic for human decay accelerating factor Transplantation 64: 1383-1392

van den Bogaerde J, White DJG, (1997) Xenogenic transplantation Br.Med.Bull. 53:904

Kobayashi T, Taniguchi S, Neethling FA, Rose AG, Hancock WW, Ye Y, Niekrasz M,Kosanke S, Wright LJ, White DJG, Cooper DKC. (1997) Delayed Xenograft Rejection ofPig-to-Baboon Cardiac Transplants After Cobra Venom Factor Therapy. Transplantation64: 1255-1261.

Zaidi A, Schmoeckel M, Bhatti F, Waterworth P, Tolan M, Cozzi E, Chavez G, LangfordG, Thiru S, Wallwork J, White DJG, Friend PJ. (1998) Life-supporting pig to primaterenal xenotransplantation using genetically modified donors. Transplantation, 65: 1584-1590

Schmoeckel M, Bhatti FNK, Zaidi A, Cozzi E, Waterworth PD, Tolan MJ, Pino-ChavezG, Warner RG, Langford GA, Dunning JJ, Wallwork J, White DJG. (1998) Orthotopic

34

Heart Transplantation in a Transgenic Pig to Primate Model [published erratum appearsin Transplantation 1998 Oct 15;66(7):943 Transplantation 65: 1570-1577.

White D, Langford G. (1998) Xenografts from Livestock. In: Modern Genetics. NewTechnologies in Animal Breeding. Ed AJ Clark. Harwood Acad, Amsterdam.

White DJG (1998) Xenotransplantation – The solution to the organ donor shortage?Science in Parliament:4-5

White DJG (1998) Transgenic methodologies to humanize a donor. ASH

White DJG (1998) Xenotransplantation. The Thoracic and Cardiovascular Surgeon

White DJG (1998) Xenotransplantation: the solution to the organ shortage crisis? Organsand Tissues 1: 25-28.

Skepper JN, Pierson RN, Young VK, Rees JA, Powell JM, Navaratam V, Cary NRB,Tew DN, Bacon PJ, Wallwork J, White DJG, Menon DK. (1998) CytochemicalDemonstration of Sites of Hydrogen Peroxide Generation and Increased VascularPermeability in Isolated Pig Hearts after Ischaemia and Reperfusion. Microscopy Res andTechnique, 42: 369-385.

Pierson RN, Pino-Chavez G, Young VK, Kaspar-Konig W, White DJG, Wallwork J.(1998) Expression of human decay accelerating factor may protect pig lung fromhyperacute rejection by human blood. J Heart Lung Transplant, 16: 231-239.

Bhatti FN, Zaidi A, Schmoeckel M, Cozzi E, Chavez G, Wallwork J, White DJG, FriendPJ. (1998) Survival of life supporting hDAF transgenic kidneys in primates is enhancedby splenectomy. Trans Proc, 30: 2467

Calne RY, Thiru, McMaster P, Craddock, White DJG, Evans DC, Dunn DC, PentlowBD, Rolles K. (1998) Cyclosporin A in patients receiving renal allografts from cadaverdonors. 1978 [classical article] J.Am.Soc.Nephrol 9:1751

Zaidi A, Bhatti FNK, Schmoeckel M, Cozzi E, Chavez G, Wallwork J, White DJG,Friend PJ. (1998) hDAF Transgenic Pig Kidneys are physiologically compatible withprimates. Trans Proc. 30: 2465-2466

Cozzi E, White DJG, (1998) Xenotrapianti. In: Enciclopedia Medica Italiana. Ed Utet(Rome)

Waterworth PD, Cozzi E, Tolan M, Langford G, Braidley P, Chavez G, Dunning J,Wallwork J, White DJG, Wallwork. (1998) Life supporting pig to baboon heartxenotransplantation J. Heart Lung Transplantation 17: 1201-1207

35

Taylor CJ, Tang KG, Smith Si, White DJG, Davies HF. (1998) HLA-specific antibodiesin highly sensitized patients can cause a positive crossmatch against pig lymphocytes.Transplantation 65: 1634-41

Schmoeckel M, Wallwork J, White DJG. (1999) Cardiac Xenograft Organs fromTransgenic Pigs. In: Advanced Therapy in Cardiac Surgery, p.520-526.

Blair KSA, Zorn GL, Zhang JP, Qiun QH, Parker RE, Joseph KJ, Marsh JW, White DJG,Harrison R, Pierson RN (1999) Complement Inhibition with sCR1 administration andhDAF expression attenuates hyperacute rejection of pig lung by human blood.Transplantation 67: 614

Storck M, Abendroth D, Prestel R, Pina-Chavez G, Miller-Hocker J, White DJG,Hammer C. (1999) Transgenic swine as potential organ donors? Results of the ex-vivohemoperfusion of hDAF transgenic kidneys with human blood. Zentrabl. Chir. 123: 785-792

Bhatti FN, Zaidi A, Schmoeckel M, Cozzi E, Chavez G, Dunning JJ, Wallwork J, WhiteDJG (1999) Three month survival of hDAF transgenic pig hearts transplanted intoprimates Trans Proc 31: 958

Schmoeckel M, Bhatti FNK, Zaidi A, Cozzi E, Chavez G, Friend PJ Wallwork J, WhiteDJG. (1999) Splenectomy improves survival of hDAF transgenic pig kidneys inprimates. Trans Proc 31: 961

Ishida H, Richards A, Davies H ffS, White DJG (1999) Expression of human decayaccelerating factor on cultured bone marrow cells from transgenic pigs. Trans Proc 31:707-710

Schmoeckel M, Cozzi E, Chavez G, Dunning JJ, Wallwork J, White DJG (1999)Xenotransplantation of hDAF transgenic pig hearts Zentralbi Chir 124: 604-608

Oberholzer J, Yu D, Triponez F, Cretin N, Andereggen E, Mentha G, White DJG,Buehler L, Morel P, Lou J. (1999) Decomplementation with cobra venom factor prolongssurvival of xenografted islets in a rat to mouse model. Immunology 97: 173-180

Soin B, Cozzi E, Vial C, Ostlie D, White DJG. (1999) Renal Xenotransplantation. BritishJournal of Renal Medicine pp. 9-12

Cozzi E, White DJG (1999) Xenotrapianto. Enciclopedia medica italiana

Cozzi E, Masroor S, Soin B, Vial C, White DJG (1999) Progress in Xenotransplantation.J Nephrology 53: 13-18

36

Masroor S, Cozzi E, Soin B, Vial C, Chavez G, Smith K, Bradley JR, White DJG, FriendPJ. (1999) Absence of hyperacute rejection and preservation of function in hDAFtransgenic pig kidneys exposed to prolonged cold ishaemia. Trans. Proc. 32: 965-6

Oberholzer J, Yu D, Triponez F, Cretin N, Anderregen E, Menths G, White DJG, BuehlerL, Morel P, Lou J (1999) Decomplementation with cobra venom factor prolongs survivalof xenotransplanted islets in a rat to mouse model. Immunology 97: 173-180

Schmoekel M, Bhatti F, Zaidi A, Cozzi E, Chavez G, Wallwork J, White DJG (1999)Splenectomy improves survival of hDAF transgenic pig kidneys in primates. Trans Proc31: 961

Schmoekel M, Wallwork J, White DJG (1999) Cardiac xenograft organs fromtransgenic pigs. Advanced therapy in cardiac surgery p 520-526

Schmoekel M, Cozzi E, Chavez G, Dunning J, Wallwork J White DJG (1999)Xenotransplantation of hDAF transgenic swine hearts. Zentralbl. Chirug 124: 604-8

Soin B, Cozzi E, Vial C, Ostlie D, White DJG (1999) Renal Xenotransplantation.British Journal of Renal Medicine, 28: 9-12

Storck M, Abendroth D, Prestel R, Pino-Chavez G, Miller-Hocker J, White DJG,Hammer C. (1999) Transgenic swine as potential organ donors? Results of the ex-vivohemoperfusion of hDAF transgenic kidneys with human blood. Zentralbl. Chirug 123 (7)785-792

Ishida H, Richards AC, Cozzi E, White DJG (1999) Expression of hDAF on cultures ofbone marrow cells from transgenic pigs. Trans Proc 31: 707-710

Cozzi E, Soin B, Holmes B, White DJG (2000) Genetic engineering of the donor as an approach to clinical xenotransplantation. Transplant.Proc.32:2701-2703.

Ramirez P, Chavez R, Majado M, Munitiz V, Munoz A, Hernandez Q, Palenciano CG, Pino-Chavez G, Loba M, Minguela A, Yelamos J, Gago MR, Vizcaino AS, Asensi H, Cayuela MG, Segura B, Marin F, Rubio A, Fuente T, Robles R, Bueno FS, Sansano T, Acosta F, Rodriguez JM, Navarro F, Cabezuelo J, Cozzi E, White DJG, Calne RY, Parrilla P: (2000) Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days. Transplantation;70:989-998.

Loss M, Vangerow B, Schmidtko J, Kunz R, Jalali A, Arends H, Przemeck M, Ruckholt H, Leuwer M, Kaup FJ, Rensing S, Cozzi E, White DJG, Klempnauer J, Winkler M: (2000) Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model. Xenotransplantation.;7:186-196.

37

Loss M, Przemeck M, Schmidtko J, Kunz R, Jalali A, Arends H, Lorenz R, Rensing S, Kaup FJ, Jager K, White DJG, Klempnauer J, Winkler M: (2000) Factors determining theonset of hyperacute rejection following discordant porcine-to-cynomolgus monkey kidney xenotransplantation. Transplant.Proc.;32:1098.

Loss M, Przemeck M, Schmidtko J, Arends H, Kunz R, Jager K, Jalali A, Rensing S, Kaup J, Cozzi E, White DJG, Klempnauer J, Winkler M: (2000) Long-term survival of cynomolgus monkeys following pig-to-primate kidney xenotransplantation using h-DAF transgenic donor organs. Transplant.Proc.;32:1095-1096.

Masroor S, Cozzi E, Soin B, Vial C, Chavez G, Smith KG, Bradley JR, White DJG, Friend PJ: (2000) Absence of hyperacute rejection and preservation of function in HDAF transgenic pig kidneys exposed to prolonged cold ischaemia. Transplant.Proc.;32:965-966.

Quan D, Bravery C, Chavez G, Richards A, Cruz G, Copeman L, Atkinson C, Holmes B, Davies H, Cozzi E, White DJG (2000) Identification, detection, and in vitro characterization of cynomolgus monkey natural killer cells in delayed xenograft rejectionof hDAF transgenic porcine renal xenografts. Transplant.Proc.;32:936-937.

Manez R, Crespo F, Gonzalez E, Centeno A, Juffe A, Arnal F, Cozzi E, White DJG, Duthaler R, Kinzy W, Oehrlein R, Katopodis A: (2000) Neutralization of anti-alphaGalactosyl antibodies without immunosuppression prevents hyperacute rejection butnot acute vascular rejection of pig organs transplanted into baboons. Transplant.Proc.;32:888-889.

Cozzi E, Masroor S, Soin B, Vial C, White DJG: (2000) Progress in xenotransplantation. Clin.Nephrol.;53:13-18.

Vial CM Ostlie DJ Bhatti FN Cozzi E Goddard M Chavez GP Wallwork J White DJG Dunning JJ (2000) Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 19 224-9

Masroor S, Cozzi E, Soin B, Vial C, Chavez G, Smith KG, Bradley JR, White DJG, Friend PJ: (2000) Absence of hyperacute rejection and preservation of function in HDAF transgenic pig kidneys exposed to prolonged cold ischaemia. Transplant.Proc. 2000;32:965-966.

Quan D, Bravery C, Chavez G, Richards A, Cruz G, Copeman L, Atkinson C, Holmes B, Davies H, Cozzi E, White DJG: (2000) Identification, detection, and in vitro characterization of cynomolgus monkey natural killer cells in delayed xenograft rejectionof hDAF transgenic porcine renal xenografts. Transplant.Proc.;32:936-937.

Bennet W, Bjorkland A, Sundberg B, Brandhorst D, Brendel M, Richards A, White DJG, Nilsson B, Groth C, Korsgren O. (2000) Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from

38

normal and hDAF transgenic pigs. In Isolated Islets of Langerhans Trigger an Instant Blood Mediated Inflammatory Reaction Ed W Bennet Ch IV

Cozzi E, Bhatti F, Schmoekel M, Chavez G, Smith K, Zaidi A, Bradley J, Thiru S,Goddard M, Vial C, Ostlie D, Wallwork J, White DJG (2000) Long term survival of non-human primates receiving life supporting transgenic porcine kidney xenografts.Transplantation 7: 15-21

Soin B, Ostlie D, Cozzi E, Smith K, Bradley JR, Vial C, Masroor S, Lancaster R, WhiteDJG (2000) Growth of porcine kidneys in their native and xenograft environment.Xenotransplantation 7 : 96-100

Bennet W, Sundberg B, Lundgren T, Tibell A, Groth C, Richards A, White DJG, ElgueG, Larrson R, Nilsson B, Korsgren O. (2000) Damage to porcine Islets of Langerhansafter exposure to human blood in vitro, or after intraportal transplantation to cynomolgusmonkeys. Transplantation 69 711-719.

Manez R, Ruiz de Balbuena C, Juffe A, Crespo F, Filguiera P, Katopodis A, Cozzi E,White DJG. (2001) Immunosuppression with cyclophosphamide at induction only,neoral, ERL and Corticosteroids prevents cellular rejection in hDAF pig to baboonheterotopic heart transplantation. Transplantation 69 (8) S251

Lorenz R, Loss M, Schmidtko J, Kunz R, Jalali A, Przemeck M, White DJG, KlempnauerJ, Winkler M: (2001) Influence of cold ischemia time on hyperacute rejection and delayed graft function of porcine kidneys following discordant xenotransplantation from pig to cynomolgus monkey. Transplant.Proc.;33:740-741.

Holmes BJ, Richards A, McLaughlin M, Cruz G, Copeman L, Bycroft S, Schuurman H, White DJG, Davies H, Cozzi E: (2001) Antibody responses in early graft rejection in pig-to-primate renal xenotransplantation. Transplant.Proc.;33:717-718.

Loss M, Vangerow B, Schmidtko J, Kunz R, Hecker J, Schroder C, Ruckholt H, Kaup FJ,Soin B, Cozzi E, Piepenbrock S, Klempnauer J, White DJG, Winkler M: (2001) Acute vascular rejection of h-DAF transgenic porcine kidneys in immunosuppressed cynomolgus monkeys is associated with systemic and intragraft complement activation. Transplant.Proc.;33:715.

Soin B, Smith KG, Zaidi A, Cozzi E, Bradley JR, Ostlie DJ, Lockhart A, White DJG, Friend PJ: (2001) Physiological aspects of pig-to-primate renal xenotransplantation. Kidney Int.;60:1592-1597.

Lundgren T, Bennet Wtibell A, Soderlund J, Sundberg B, Song Z, Richards A, White DJG, Groth CG, Kosgren O. (2001) Soluble complement receptor 1 (TP10) preserves adult porcine islet morphology after intraportal transplantation into cynomolgus monkeys. Transplant Proc; 33: 725-726

39

Bennet W, Bjorkland A, Sundberg B, Brendel MD, Richards A, White DJG, Groth, Kosgren O (2001) Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from transgenic pigs. Transplantation; 72: 312-319

Zhu T, Bradley A, White DJG, Chen ZK (2001) Effect of ERL 080A RAD and Neoral onhamster to rat heart xenograft survival. Transplant. Proc; 33: 3871-2

Richards AC, Davies HF, Copeman LS, Holmes BJ, Chavez G, Schuurmann HJ, White DJG, Cozzi E; (2002) Serum anti-pig antibodies as a potential indicator of acute humoral rejection in pig-to cynomolgus monkey kidney transplantation; Transplantation; 73: 881-889

Ramirez P, Chavez R, Hernandez O, Pino-chavez G, Yelamos J, Sansano T, Rodriguez Jm, Navarro F, Cozzi E, White DJG, Parilla P; (2002) Transgenic pig-to-baboon liver xenotransplantation: clinical, biochemical and immunological pattern of delayed vascularrejection. Trans. Proc; 34 319-320

Cabezuelo JB, Ramirez P, Chavez R, Hernandez O, Pino-chavez G, Yelamos J, Sansano T, Rodriguez Jm, Navarro F, Cozzi E, White DJG, Parilla P; (2002) Assessment of renal function during the postoperative period following liver xenotransplantation from transgenic pig to baboon. Transplant. Proc; 34: 321-2

Palenciano CG, Segura B, Ramirez P, Chavez R, Hernandez O, Pino-chavez G, YelamosJ, Sansano T, Rodriguez Jm, Navarro F, Cozzi E, White DJG, Parilla P; (2002) Acid baseand electrolyte disturbance in an experimental model of orthotopic liverxenotransplantation from pig-to- baboon after graft reperfusion: differences between h-DAF livers and unmodified livers. Transplant. Proc. 34: 325-326

Schuurman HJ, Chavez G, Thomas L, Cozzi E, White DJG (2002) Incidence ofhyperacute rejection in pig-to primate transplantation using organs from h-DAFtransgenic donors. Transplantation; 73: 1146-1151

Rees MA, Butler AJ, Chavez G, Wight DG, Alexander G, White DJG, Friend PJ (2002)Prolonged function of extracorporeal hDAF transgenic pig livers perfused with humanblood. Transplantation; 73:1194-11202

Butler AJ, Rees MA, Wight DG, Alexander G, White DJG, Friend PJ; (2002) Successfulextracorporeal porcine liver perfusion for 72 hr. Transplantation; 73: 1212-1218

Rees MA, Butler AJ, Davies HF, Bolton E, Wight DG, Skeeper J, White DJG. Porcinelivers perfused with human blood mount a graft-versus-host reaction (2002)Transplantation 73; 1460 1467

40

Katopodis G., Warner RG, Duthaler RO, Streiff MB, Bruelisauer A., Kretz O, Dorobek B, Persohn E, Andres H, Schweitzer A, Thoma G, Kinzy W, Quesniaux V.F, Cozzi E, Davies, H.F, Mañez R, and White DJG. Removal of anti-Gal alpha l, 3Gal xenoantibodies with an injectable Gal polymer. (2002) J. Clin. Invest. 110(12):1869-77.

J. Yang, S.M. Bernier, G.H Strejan, T.E Ichim, M. Li, X. Xia, , D. Zhou, X. Huang, DJG White, R. Zhong (2002) LF15-0195 Generates Tolerogenic Dendritic Cells by Suppression of NF-! B Signaling through Inhibition of IKK Activity. (2003) Journal of Leukocyte Biology 74(3): 438-447

Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J, Huang X, Garcia B, White DJG, Dutartre P, Jevnikar AM, and Zhong R. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. (2003) J Immunol. 1; 170(3): 1304-12.

Azimzadeh A, Zorn III, GL, Blair KSA, Zhang JP, Pfeiffer S, Harrison RA, Cozzie E, White DJG, and Pierson III, RN. Hyperacute lung rejection in the pig-to-human model. 2. Synergy between soluble and membrane complement inhibition. (2003) Xenotransplantation 10: 120-131

Schuurman HJ, Pino-Chavez G, Phillips MJ, Thomas L, White DJ, Cozzi E. (2002) Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation;73:1146-51.

Cozzi E, Vial C, Ostlie D, Farah B, Ghavez G, Smith KGC, Bradley JR, Thiru S, Davies H, Wallwork J, White DJG, Goddard M, and Friend P J. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. (2003) Xenotransplantation 10: 300-310.

Schroder C, Pfeiffer S, Wu G, Zorn GL, Ding L, Allen C, Harrison RA, White DJ,Azimzadeh AM, Pierson RN 3rd Effect of complement fragment 1 esterase inhibition on survivalof human decay-accelerating factor pig lungs perfused with human blood. (2003) J. HeartLung Transplant 22(12):1365-75.

Li M, Qian H, Ichim TE, Ge WW, Popov IA, Rycerz K, Neu J, White DJG, Zhong R, Min WP. Induction of RNA interference in dendritic cells (2004) Immunol Res 30 215-30

Ichim, Thomas E, Mu Li, Hua Qian, Igor A. Popov, Katarzyna Rycerz, Xiufen Zheng, DavidWhite, Robert Zhong and Wei-Ping Min. RNA interference: A potent tool for gene-specifictherapeutics. (2004) American Journal of Transplantation 4: 1227-36.

Steffen Pfeiffer, MD, George L Zorn III, MD, Kelly SA Blair, MD, Steve M Farley, Guosheng

41

Wu, MD, PhD, Henk-Jan Schuurman, MD, Agnes M Azimzadeh PhD, David JG White PhD,Richard N Pierson III, MD. Hyperacute Lung Rejection in the Pig-to-Human Model. Evidencefor complement- and antibody independent mechanisms (2005) Transplantation 79: 662-71.

Teran-Escandon D, Teran-Oritz L, Ormsby-Jenkins C, Evia-Viscarra ML, White DJG, Valdes-Gonzalez-Salas R. Psycosocial aspects of xenotransplantation: survey in adolescent recipients of porcine cells (2005) Transplant Proc 37 521-4

Rafael A. Valdés-González, Luis M. Dorantes, G. Nayely Garibay, Eduardo Bracho-Blanchet, Armando J. Mendez, Roberto Dávila-Pérez, Robert B. Elliott, Luis Terán, David J.G. White. Xenotransplantation of Porcine Neonatal Islets of Langerhans and Sertoli Cells: A Four Year Study. (2005) Europ. J. Endocrinology 153: 419-427

Sun H, Chen G, Liu W, Kubelik D, Yang H, White DJ, Zhong R, Garcia B The Influence of Baseline Expression of Human Decay Accelerating Factor Transgene on Graft Survival and Acute Humoral Xenograft Rejection (2005) Transplantation;80:1331-1339.

Wu G, Pfeiffer S, Schroder C, Zhang T, Nguyen BN, Lea W, Kelishadi S, Atkinson JB, Schuurman HJ, White DJ, Pierson RN, III: Co-stimulation blockade targeting CD154 andCD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft. Xenotransplantation 2005, 12:197-208.

Chen G, Qian H, Starzl T, Sun H, Garcia B, Wang X, Wise Y, Liu Y, Xiang Y, CopemanL, Liu W, Jevnikar A, Wall W, Cooper DK, Murase N, Dai Y, Wang W, Xiong Y, White DJ, Zhong R: Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005, 11:1295-1298.

Chen G, Sun H, Yang H, Kubelik D, Garcia B, Luo Y, Xiang Y, Qian A, Copeman L, Liu W, Cardella CJ, Wang W, Xiong Y, Wall W, White DJ, Zhong R ‘The Role of Anti-non-Gal Antibodies in the Development of Acute Humoral Xenograft Rejection of hDAFTransgenic Porcine Kidneys in Baboons Receiving Anti-Gal Antibody Neutralization Therapy’ Transplantation; 81(2):273-283. 2006

White DJG Genetic Engineering of pigs to provide organs for xenotransplantation Current Opinion in Organ Transplantation 11 160-165 2006

Tai JH, Foster P, Rosales A, Feng B, Hasilo C, Martinez V, Ramadan S, Snir J,Melling CWJ, Dhanvantari S, Rutt B, White DJG Imaging of islets labelled With Magnetic Nanoparticles at 1.5 Tesla Diabetes 55 2006

Wu G, Pfeiffer S, Schroder C Zhang T, Nguyen B, Kelishadi S, Atkinson JB, Schurman H, White DJG, Pierson RN Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes. Xenotransplantation 14 34-47 2007

42

White DJG Islet xenotransplantation. Current Opinion in Organ Transplantation 12 148-153 2007

Valdes-Gonzalez, R., White, D J G., Dorantes, L. M., Teran, L., Garibay, G. N., Ormsby, C. E., Torres M, and Ramirez-Gonzalez, B. Three year follow up of a type 1 diabetes mellitus patient with an islet xenotransplant. Clin Transplant 21, 352-357. 2007.

Valdes-Gonzalez RA, Dorantes LM, Garibay GN, Bracho-Blanchet E, Davila-Perez R, Teran L, Ormsby CE, Ayala-Sumuano JT, Copeman L, White DJG: Unexpected immunoresponse to Gal and APA antigens in diabetic type 1 patients receiving neonatal pig islets after 6 years. J Clin Immunol;27:266-274. 2007

White D.J.G. Creating animals for cell xenotransplantation: in Cellular Transplantation Pub Elsevier Ed Halberstadt C. & Emerich D. Ch 4 pp 43-56 2008

Hasilo, C P., Vilk, G., Melling, C W.J., Pepper, A., MacGillivary, A., Sverzhinsky, A., Gall, C., Siroen, D M., Grise, K., and White, D.J.G. Enhancement of diabetes reversal in balb/c athymic nude mice with optimal ratios of adult porcine islets of langerhans to adultporcine Sertoli cells. Transplantation 86: 562-563 2008

White, D.J.G, Hasilo, C., Vilk, G., Siroen, D.M., Pepper, A., Gall, C., MacGillivary, A., and Melling, C.W.J. Long term survival and function of adult porcine islets co-transplanted with adult porcine Sertoli cells into rats without immunosuppression. Transplantation 86:91-92 2008

Joo Ho Tai, Hongtao Sun,† Weihua Liu, C. W. James Melling, Craig Hasilo, David J. G. White: Isolating Human Islets of Langerhans Causes Loss of Decay Accelerating Factor (CD55) on β-Cells. Cell Transplantation 17: 1349-1360 2009

Jirak, D. Kriz, J. Strzeleck, M. Yang, J. Hasilo, C. White, D.J.G. Foster, P.J. Monitoring the survival of islet transplants by MRI using a novel technique for the automated detection and quantification. MAGMA 4: 257-265 2009 White DJG. Hasilo GC. Vilk GR. Pepper AR. Mazzuca DM. MacGillivary AS. MellingCWJ.. Long term Survival and Function of porcine islets co-transplanted with adultSertoli cells into non-immunosuppressed rats and mice. Xenotransplantation 16: 3532009

Pepper AR. Mazzuca DM. Vilk GR. Hasilo GC. Melling CWJ. White DJG. Developmentof a novel rapid accurate pre-transplant in vitro assay to determine the in vivo function oftransplanted islets of Langerhans. Xenotransplantation 16: 354 2009

Vilk GR. Pepper AR. Mazzuca DM. Hayatsu J. White DJG. Insulin resistance and thepresence of thymus independent anti-insulin IgG antibody production.Xenotransplantation 16: 382 2009

43

Pepper, AR., Gall C, Mazzuca DM , Melling DM and White DJG. Diabetic rats and mice are resistant to porcine and human insulin: flawed experimental models for testing islet xenografts. Xenotransplantation 16: 502-510 2009

Rafael Valdes-Gonzalez, Luis M. Dorantes, Carlos Bracho-Blanchet, Ana Rodríguez-Ventura White DJG: No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long term porcine islet xenotransplants. J. Med Virol. ;82:331-4 2010Valdes-Gonzalez R, Rodriguez-Ventura AL, White DJ: Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets. Clin Exp Immunol. 162:537-422010

Pepper AR, Hasilo CP, Melling CWJ, MazzucaDM, Vilk G, Zou G, White DJG: The sizeto Oxygen Consumption Rate Reliably Predicts Reversal of Diabetes Posttransplant. Cell Transplant. 21: 2797-2084 2012

Pepper AR, Welch I, Bruni A, MacGillivary A, MazzucaDM, White DJG, Wall W: Establishment of a stringent large animal model of insulin dependent diabetes for islet autotransplantation: Combination of pancreatectomy and Streptozotocin. Pancreas. 42: 329-338 2013

Books

• White DJG. (Ed). (1982) Cyclosporin A: Elsevier Biomedical, Amsterdam.• Cooper D, Kemp EJ, Reemtsma K, White DJG (Eds). (1991) Xenografting.

Springer-Verlag• Cooper DKC, Kemp E, Platt JL, White DJG (Eds). (1997) Xenotransplantation:

The Transplantation of Organs and Tissues Between Species (2nd Ed). Springer-Verlag, Berlin.

Patents:

• Biocompatible Materials pat. no. 8922987 (1989)• Pharmaceutical formulations pat. no. 9115088 (1990)• Modified biological material pat. no. 95118520 (1995)• Adult Sertoli cells pat. no 101106001 (2007)

44